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 Porcine circovirus 2 (PCV2) is a small single stranded DNA virus responsible for 
a group of detrimental diseases referred to as Porcine Circovirus Associated Diseases 
(PCVAD). Observed variation in incidence and severity of PCVAD between pigs 
suggests a host genetic role in facilitating PCV2 pathogenesis. This study builds on prior 
research by Engle et al. (2014), who performed a large-scale genome-wide association 
study of 974 crossbred pigs experimentally infected with a PCV2b isolate and provided 
evidence of a host genetic role in PCV2 viremia, immune response, and growth. Two 
major Quantitative Trait Loci (QTL) were identified for viral load located on 
chromosome 7 (SSC7) near the swine leukocyte antigen complex class II (SLAII) locus 
and the proximal end of chromosome 12 (SSC12).  The SNP with largest association, 
ALGA0110477 (SSC12), explained 11.1% of the genetic variance and 7.4% of the 
phenotypic variance for viral load. 
 Dissection of the SSC12 QTL region using gene annotation and both genomic and 
RNA sequencing uncovered a novel missense polymorphism within SYNGR2 
(p.Arg63Cys) that exhibited the largest association with PCV2 viremia and immune 
response. In vitro gene silencing of SYNGR2 was performed on porcine kidney 15 cell 
line (PK15) using siRNA designed against the SYNGR2 mRNA sequence. A substantial 
   	  
	   	   	   	  
decrease in SYNGR2 mRNA expression (82.2%) was achieved and corresponded with a 
significant reduction in PCV2 titer beginning at 48 hours post infection (P<0.05) 
compared to scramble siRNA and non-transfected control cells, indicating a role of 
SYNGR2 in viral replication. The SYNGR2 p.Arg63Cys mutation is located within a 
protein domain conserved across mammals and results in an amino acid substitution 
(ArgàCys) unique to swine. The impact of SYNGR2 on PCV2 replication and location of 
a non-conservative substitution within a key domain provides strong evidence that the 
SYNGR2 p.63Cys variant underlies the observed genetic effect on viral load by 
potentially interfering with SYNGR2 activity. These findings provide important insight 
into the role of host genetics in PCV2 pathogenesis.  
 
Key Words: PCV2, susceptibility, viremia, immune response, replication, siRNA, 
synaptogyrin-2, SYNGR2
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CHAPTER 1 
LITERATURE REVIEW 
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History of PCV2 
 Today, Porcine Circovirus 2 (PCV2) is recognized as a key threat to swine 
populations worldwide. However, its characterization as a distinct and disease causing 
pathogen did not occur until many years after its suggested emergence in 1962 [1] . The 
virus was first identified in 1974 as a contaminate of a porcine kidney cell line (ATCC-
CCL31) that caused no observable cytopathic effects [2, 3]. This contaminant was 
initially believed to be a picornavirus-like virus, but upon further analysis was 
determined to be a single-stranded DNA virus with a covalently closed-circular genome, 
about 1.76kb in length [3, 4]. The composition and properties of this virus were different 
from any known animal pathogen and specific antibodies were found in sera collected 
exclusively from pigs, indicating they were the likely species of origin [4]. As a result, 
the unique virus was given the name porcine circovirus (PCV) and has since been 
assigned to the Circoviridae family [4, 5]. 
Initial experimental infection of pigs with the PK-15 PCV isolate induced no 
signs of clinical disease or evidence of viral replication, however, PCV specific 
antibodies were detected in blood samples collected from the infected pigs [6]. Another 
experimental infection using colostrum-deprived pigs validated the lack of pathogenesis, 
but was able to detect PCV antigen in tissues throughout the body indicating viral 
replication [7]. PCV specific antibodies were also present in asymptomatic 
conventionally raised Canadian pigs and wild boars from the Berlin region of Germany. 
Thus, PCV was deemed a non-pathogenic virus common of all swine [2, 6, 7]. 
In 1991, a new disease emerged in a previously healthy herd of Canadian pigs 
free of any major enteric and respiratory diseases [8, 9]. Clinical signs appeared in 
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affected piglets about 2-3 weeks post-weaning and included wasting, dyspnea, jaundice, 
and lymphoid depletion [10]. This disease soon became known as Post-Weaning 
Multisystemic Wasting Syndrome (PMWS), with the first description of PMWS given in 
1996 [10]. PMWS cases have since been documented worldwide in piglets 5-12 weeks of 
age and are associated with increased rates of mortality [8]. Subsequent investigations 
into the culprit behind PMWS uncovered a potential link between disease onset and a 
novel type of PCV, overturning the precedent that PCV was strictly non-pathogenic.   
In 1998, a virus similar in size and morphology to the PK-15 PCV isolate was 
found in tissue samples collected from Californian and French pigs with clinical signs of 
PMWS, but not in healthy controls [11]. The ability to detect PCV-like nucleic acid using 
in situ hybridization with a PCV genomic probe indicated that this virus was genetically 
similar to the PK-15 PCV isolate, however, a difference in reactivity to monoclonal 
antibodies suggested that it possessed distinct antigenic properties [11]. Genomic 
comparison revealed that the nucleotide sequence similarity was less than 80% between 
isolates from PMWS affected pigs and the PK-15 PCV isolate [12, 13]. Based on these 
findings, a proposal was made to break PCV into two groups with the new potentially 
pathogenic form classified as Porcine Circovirus type 2 (PCV2) and the non-pathogenic 
PK-15 isolate as Porcine Circovirus type 1 (PCV1) [12].  
Although PCV2 was detected in archived tissue samples collected as early as 
1962 from pigs of Northern Germany, PCV2-associated pathological changes and lesions 
did not appear in samples until 1985 [1]. In fact, the ability to detect viral DNA in 
samples between 1962 and 1984 was highly variable with an estimated prevalence of 
about 2.5%. However, this estimate sky-rocketed to over 30% in samples from 1985 and 
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onward, coinciding with the first incidents of associated lesions and reports of PMWS [1, 
14]. Specifically, the prevalence of PCV2 within PMWS affected farms was found to be 
much higher than in non-affected farms as well as in PMWS affected pigs compared to 
non-affected pigs [15]. PCV2 has since been implicated in a variety of other diseases and 
symptoms aside from PMWS, such as Porcine Respiratory Disease Complex (PRDC), 
Porcine Dermatitis and Nephropathy Syndrome (PDNS), weight loss, reproductive 
failure, and lymphoid depletion [16-19]. In 2006, these diseases became collectively 
referred to as Porcine Circovirus Associated Diseases (PCVAD) [20].  
 
Porcine Circovirus Associated Diseases 
 According to the American Association of Swine Veterinarians (AASV), PCVAD 
may be subclinical or consist of one or more clinical manifestations including: 
multisystemic disease with wasting, respiratory problems, PDNS, enteric conditions, 
reproductive disorders, and high mortality that are present solely or combined in a group 
of animals [20]. The Veterinary Diagnostic Laboratory at Iowa State University, 
classifies systemic infection and PCV2-associated pneumonia, enteritis, reproductive 
failure, and PDNS under PCVAD in the diagnostics database [20]. In an individual pig, 
PCVAD is diagnosed by microscopic lesions with an abundance of PCV2 antigen. 
Evaluation of intestine, lung, and lymphoid tissue for the presence of PCV2 antigen by 
immunohistochemistry must be performed in order to determine specific PCVAD 
manifestation [20].  
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a) Subclinical PCV2 Infection 
A diagnosis of subclinical PCV2 infection is characterized by low levels of PCV2 antigen 
that are not responsible for any clinical disease. There may be no or minimal lesions, with 
infection often limited to one or two lymph nodes [20].  
 
b) Post-Weaning Multisystemic Wasting Syndrome (PMWS) and Systemic Infection 
Systemic PCV2 infection is characterized by lymphohistiocytic or granulomatous 
inflammatory lesions in lymphoid tissues, lung, intestines, liver, and/or heart [20]. The 
first symptom is often weight loss, jaundice, or failure to thrive [20]. In order for PCV2 
infection to be diagnosed as systemic, PCV2 antigen must be found in more than one 
lymphoid tissue, one lymphoid tissue and one organ system, or two organ systems [17, 
20]. If found in only one organ system than the diagnosis would be one of the other 
PCVAD manifestations and not systemic infection [20]. PMWS falls within the realm of 
systemic PCV2 infection. In order for a pig to be diagnosed with PMWS the following 
requirements must be met: 1) wasting, weight loss, and failure to thrive with or without 
labored breathing or jaundice, 2) histological lesions with lymphoid depletion or 
granulomatous inflammation present within any organs, and 3) detection of PCV2 
infection within these lesions [21, 22].  
 
c) Porcine Respiratory Disease Complex (PRDC) 
Respiratory disease cases that involve multiple pathogens are often characterized as 
PRDC [16]. Characteristic symptoms of PRDC include decreased growth rate and feed 
efficiency, anorexia, cough, labored breathing, and fever [20]. In 2000, over 3,000 cases 
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of swine pneumonia were diagnosed at the Iowa State University Veterinary Diagnostic 
Laboratory, with 694 cases classified as PCV2-associated pneumonia [16]. Of the 694 
cases, 56% presented with concurrent Porcine Reproductive and Respiratory Syndrome 
Virus (PRRSV) infection, 19% with Mycoplasma hyopneumoniae, and 12% with Swine 
Influenza Virus (SIV) [16]. Three case studies, revealed that concurrent infection with 
PCV2 and PRRSV, M. Hyopneumoniae, or SIV resulted in PRDC [16]. High levels of 
PCV2 antigen found in lesions associated with granulomatous bronchointerstitial 
pneumonia with bronchiolitis and bronchiolar fibrosis lend support for role of PCV2 in 
prolonged respiratory disease [16, 20]. 
 
d) Porcine Dermatitis and Nephropathy Syndrome (PDNS)  
Characteristic symptoms of PDNS include prominent raised purple skin lesions 
commonly distributed on the hind legs, lethargy, and fever [20, 23]. Renal lesions are 
also common and indicative of glomerulonephritis believed to be due accumulation of 
antigen-antibody aggregates and immune complexes within specific tissues [20, 23]. 
PDNS is often fatal, with animals succumbing after only a short period of clinical disease 
[23]. In a case control study, PCV2 was found in 100% of PDNS affected pigs 
predominantly in the lymph nodes and tonsils [24]. Extremely high levels of PCV2 
antibodies were consistently found in the serum of affected pigs and were significantly 
higher compared to control pigs [24]. Accumulation of IgG and IgM antibodies as well as 
complement factors and CD8+ cells were also found in the kidneys of affected animals, 
indicating that excessive amounts of PCV2 antibodies caused by PCV2 infection may 
induce PDNS [24].  
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e) PCV2-Associated Enteritis 
Clinically, PCV2-associated enteritis mimics ileitis due to Lawsonia intracellularis 
presenting with diarrhea, thickened intestinal mucosa, and enlarged mesenteric lymph 
nodes [20]. Six weaned pigs were diagnosed with PCV2-associated enteritis using 
histopathology, viral isolation, and in situ hybridization [25]. From this, the authors 
propose that in order to diagnose PCV2-associated enteritis the following criteria must be 
met: 1) presence of diarrhea, 2) typical lesions are found in Peyer’s patches, but not other 
lymph nodes, and 3) PCV2 DNA or antigen must be detected within these lesions [25].  
 
f) PCV2-Associated Reproductive Failure 
Although rare amongst breeding populations, affected herds present with increased 
number of abortions, stillbirths, mummifications, and preweaning mortalities [20, 26]. 
Field cases indicate that myocarditis is the most common lesion to be found in stillborn 
or neonatal pigs along with elevated levels of PCV2 antigen [19]. Reproductive 
abnormalities have also been induced through experimental intrauterine infection of 
fetuses with PCV2, supporting the classification of PCV2 as a reproductive pathogen 
[27]. 
 
Taxonomy, Characteristics, and Genomic Organization 
 PCV1 and PCV2 belong to the Circoviridae family and are classified under the 
Circovirus genus. Members of the Circoviridae family are small, non-enveloped, single-
stranded DNA viruses known to infect both pigs and birds [5, 28]. They have circular 
genomes approximately 1.8 to 2.3kb in length with a common stem loop structure 
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containing the origin of replication (Ori) [20, 29, 30]. The genomic organization of 
circoviruses and their mechanisms of replication closely mirror those of plant 
geminiviruses and nanoviruses [30]. In fact, further analysis of the Rep protein revealed a 
substantial degree of similarity between the n-terminal regions in circoviruses and 
nanoviruses [31]. However, the c-terminal region of the PCV Rep protein more closely 
resembles an RNA binding protein of a vertebrate RNA calicivirus [31]. Therefore, it has 
been proposed that PCV evolved after a recombination event between a nanovirus and 
calicivirus.  
There are currently 11 species of circoviruses including both types of PCV and 
various avian circoviruses [30]. PCV1 and PCV2 are the smallest of the circovirus 
species as well as among the smallest known viruses able to infect mammals and carry 
out autonomous replication [30, 32, 33] . The PCV virion is composed of 60 capsid 
protein subunits arranged in 12 pentamer clustered-units to form an icosahedron with T=1 
symmetry that is 17±1.3nm in diameter [14, 30, 32]. The circular single-stranded DNA 
genome packaged within these viral particles is approximately 1.7kb in length, encoding 
only what is required for replication and infection [30].  
Recently a new genotype of porcine circovirus, PCV3, was identified in pigs from 
Missouri, Minnesota, and South Dakota with cardiac and multi-systemic inflammation 
[34]. The strain was identified by metagenomic analysis. The Rep and Cap proteins of 
PCV3 share the most homology, 55% and 35% respectively, with a circovirus found in 
bat feces and less homology with PCV1 and PCV2, indicating PCV3 to be a novel 
member of the Circovirus genus and the third found in pigs [34].  
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Both PCV1 and PCV2 have 11 potential Open Reading Frames (ORFs), two of 
which are necessary for viral replication and assembly [35]. ORF1 encodes the replicase 
proteins, Rep and Rep’, and ORF2 encodes the capsid protein. The PCV genome is 
considered ambisense because ORF1 and ORF2 are aligned in opposite directions, such 
that ORF1 is oriented in the sense direction and ORF2 in the antisense direction relative 
to the Ori [14, 30]. The Rep protein is encoded by the full ORF1 transcript (35.6 kDA), 
while Rep’ results from an alternatively spliced ORF1 transcript (19.2 kDA) [29, 36]. 
Both proteins are required for replication in PCV1 and PCV2 with the capacity to 
instigate replication at heterologous Ori [37]. The proteins differ slightly in size between 
PCV1 and PCV2, however, four conserved sequence motifs were identified and deemed 
crucial for Rep to initiate replication with any truncation or point mutation within a motif 
leading to protein inactivation [36]. Three of these motifs are typical for proteins utilized 
in rolling circle replication and the other contains the consensus sequence for a dNTP-
binding box (GKS) [29, 36]. Additionally, an interferon-stimulated response element 
(ISRE) was discovered in the Ori of the PCV2 genome that was shown to affect in vitro 
interferon-mediated enhancement of PCV2 replication when present in an intact virus 
[30, 38]. The capsid protein is approximately 30 kDA in size and identified as the 
primary structural protein with the ability to self-assemble into capsid-like particles that 
encapsulate the PCV genome [39]. 
There are two other ORFs that encode unique non-structural viral proteins not 
involved in replication, but in other mechanisms of PCV2 infection. The ORF3 protein 
differs significantly in size between PCV1 (23.2 kDA) and PCV2 (11.9 kDA), with only 
about 62% sequence homology [35]. It is primarily found in the nucleus of infected cells, 
 
 	  
	   	  
 
10 
 
peaking around 48 hours post infection and has been implicated in PCV2-induced 
apoptosis via activation of caspase-8 and caspase-3 pathways [40]. As a result, it is 
believed to facilitate local viral spread by catalyzing early viral release from infected 
cells as well as systemic dissemination by inducing macrophage phagocytosis of 
apoptotic cells [41]. ORF4 completely overlaps ORF3 and encodes a 13.3 kDA protein in 
PCV1 and a 6.5 kDA protein in PCV2, with 83% sequence homology [35]. It is believed 
to counter virus-induced apoptosis by regulating expression of the ORF3 protein as well 
as reduce viral replication via interactions with ORF1 mRNA during early stages of 
infection [42]. In fact, cells infected with ORF4-deficient PCV2 mutants showed 
increased ORF3 expression, caspase activity, and early viral growth [42]. 
 
Genetic Variation in PCV2 Strains 
 Although closely related, PCV2 shares only about 68-76% sequence similarity 
with PCV1 [13, 14, 30]. A greater proportion of sequence discrepancies appear in ORF2 
than ORF1 with nucleotide homologies of approximately 67% and 83% respectively [13]. 
As a result, the amino acid sequences of the ORF1 protein, Rep, is more conserved with 
85% sequence homology between PCV1 and PCV2 while the Cap protein encoded by 
ORF2 is more variable, sharing only about 65% similarity [13]. The overall nucleotide 
sequence similarity between PCV2 isolates is significantly higher with 95% homology or 
greater [12]. However, majority of differences once again occur within ORF2 with 
approximately 90% nucleotide and amino acid homology across isolates [14]. Therefore, 
it is believed that variation in the cap protein may contribute to differences in isolate 
pathogenicity [43].  
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PCV2 isolates cluster into distinct sub-groups or genotypes designated by lower 
case letters [44], which are subsequently split into clades [45]. However, classification of 
PCV2 isolates is not always clear cut due to genetic recombination between PCV2 strains 
during coinfection, which has been illustrated in multiple studies to generate chimera 
isolates resembling multiple sub-groups [46] and clades [47, 48]. Furthermore, novel 
PCV2 strains continue to emerge at a rapid pace due to a high mutation rate [49]. In fact, 
following the comparison of 160 PCV2 genomes, Firth et al. (2009) deduced that PCV2 
has the highest nucleotide substitution rate of any ssDNA virus to date, reaching levels 
more commonly achieved by RNA viruses [50].  
 Currently, PCV2 is divided into three subgroups denoted PCV2a, PCV2b, and 
PCV2c, with PCV2a and PCV2b found worldwide. The existence of two more groups, 
PCV2d and PCV2e, has been proposed based on isolates from China [51], however, the 
methodology used in this study was determined insufficient to support classification as 
separate sub-groups [52]. Analysis of archived samples dating back to the early 1980s 
indicate that PCV2a precluded PCV2b in Northern Germany and the United Kingdom [1, 
53] with similar reports corroborating this pattern in other countries, such as Denmark 
[54] and China [51]. Although PCV2a and PCV2b were present in European countries 
and China prior to 2003, phylogenetic analysis indicated a dramatic shift in 
predominance towards the PCV2b sub-group at this time [14, 30]. Shortly after, PCV2b 
also emerged in North America and Canada coinciding with increased incidences of 
PCVAD [55, 56]. PCV2c was isolated from archived tissue samples between 1980-1990 
from Danish pigs prior to PCVAD outbreaks in 2003 and 2004. Phylogenetic analysis 
revealed a shift from PCV2c to PCV2a in the 1990s followed by another shift to PCV2b 
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in the early 2000s [54]. Therefore, PCV2c may represent a precursor to both PCV2a and 
PCV2b while PCV2b may represent the most adapted sub-group associated with 
increased pathogenicity [14, 54]. 
 
PCV2 Transmission 
 The transportation of asymptomatic animals is believed to have enabled the rapid 
dissemination of virulent PCV2 strains around the world as the geographic patterns of 
PCV2 appearance mirror those of the global pig trade [49]. Transmission of PCV2 often 
occurs via direct contact through oronasal, fecal, and urinary tracts [20]. In one study, 
direct contact with pigs infected with PCV2 42 days prior resulted in transmission to 
three out of three colostrum deprived control pigs [57]. Shedding patterns of PCV2 were 
analyzed using PCR for detection of viral DNA in samples collected from 16 PCV2 
experimentally infected pigs and 313 field cases [58]. The presence of PCV2 was 
detected one day after inoculation in all oropharyngeal swabs, nasal swabs, and feces 
samples and 7 days after inoculation in whole blood and serum samples obtained from 
the experimentally infected pigs and remained positive for 70 days post infection for 
most of the samples [58]. In field cases, detection of PCV2 DNA using PCR occurred in 
30.4% of whole blood samples, 19.2% of nasal swabs, and 20.4% of fecal samples with 
the frequency of positive samples increasing in post-weaning pigs approximately 3-4 
months old [58]. Another study, including 146 pigs classified as either PMWS-affected, 
PCV2 subclinically infected, or PCV2 negative, found that in general trachea-bronchial 
swabs had the highest PCV2 load followed by serum, tonsillar, nasal, fecal, and urinary 
swabs [59]. Different levels of PCV2 were detected between the three groups, with 
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PMWS affected animals exhibiting significantly higher proportions compared to the 
subclinically infected or negative groups [59]. Therefore, the authors conclude that PCV2 
is excreted through respiratory and oral secretions as well as in feces and urine of both 
PMWS affected and subclinically infected pigs [59].  
 Evidence of vertical PCV2 transmission has also been illustrated both 
experimentally and in the field [20]. Specifically, transplacental transmission was shown 
in cases of reproductive failure, late-term abortions, and stillbirths in which PCV2 
antigen was detected in various tissues of dead piglets [19, 60]. Another study focused on 
the ability of PCV2 to infect and its effects on late term fetuses [27]. Of the 37 fetuses 
infected intramuscularly through the uterine wall between 86 and 93 days of gestation, 24 
appeared phenotypically normal and 13 were unthrifty at farrowing, mummified, or 
stillborn. PCV2 infection was detected in all 37 piglets, providing experimental evidence 
that PCV2 can infect late term fetuses as well as induce reproductive abnormalities [27]. 
Additionally, intermittent shedding of PCV2 in semen of infected boars has been 
illustrated by several studies [61-63] with PCV2 predominantly found within the seminal 
fluid and non-sperm cell fraction [61]. Despite sporadic long term shedding in semen of 
infected boars, no morphological or detrimental changes to sperm cells were observed in 
the presence of PCV2 [63]. It is not known whether PCV2 in semen is infectious or 
capable of transmission via artificial insemination, however, the potential threat this 
poses to breeding programs worldwide is cause for concern.  
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PCV2 Cellular Pathogenesis  
 The molecular mechanisms underlying PCV2 pathogenesis remain somewhat 
elusive due to inconsistencies in PCV2 virulence that make it difficult to pinpoint exactly 
how PCV2 elicits disease symptoms. However, pathogenesis is believed to begin with 
PCV2 entry via oral and nasal cavities followed by viral replication in local lymphoid 
tissues and subsequent systemic dissemination of the virus to other tissues and organs 
[64]. Circulating PCV2 can be detected in sera by 7 days post infection (dpi), but peaks 
between 14 and 21 dpi [9, 26, 65]. Widespread detection of PCV2 in a variety of tissues 
and organs can be achieved beginning between 7 and 14 dpi, however, the highest viral 
titers are most often found in lymphoid tissues [9, 66]. Lymphoid depletion is a defining 
characteristic associated with PCV2 infection that causes reduced immune function and 
increased susceptibility to secondary pathogens [10]. Thus, efficient primary infection of 
lymphoid tissues may play an essential role in PCV2 induced immunosuppression and 
overall pathogenesis.  
 PCV2 predominantly infects host epithelial, endothelial, and monocytic cells by 
binding via capsid proteins to glycosaminoglycans (GAGs) on the cell surface [67]. 
Specifically, two GAGs, heparan sulphate and chondroitin sulphate B, found on the 
surface of all cell types serve as the primary receptors of PCV2 attachment [67, 68]. 
Following attachment, PCV2 enters monocytic cells via clathrin-mediated endocytosis 
[69] and epithelial/endothelial cells via an actin and GTPase-dependent pathway [70]. 
Once internalized, PCV2 virus-like particles (VLPs) were found to organize into double-
membrane bound intracytoplasmic inclusion bodies likely formed through lysosomal 
engulfment of endocytic vesicles [71]. During this first cytoplasmic phase, VLPs were 
 
 	  
	   	  
 
15 
 
also found to be associated with both the inner and outer membranes of mitochondria, 
suggesting a potential role of this organelle in facilitating PCV2 replication and 
pathogenesis [71]. In fact, mitochondria with diminished functionality containing PCV2 
VLPs were observed in the lymph nodes of PMWS-affected animals [72].  
PCV2 translocation from the periphery of infected cells to the nucleus is essential 
for replication. To do this, PCV2 commandeers a mechanism of intracellular transport 
involving the molecular motor dynein, which is used by the host to transport endosomal 
cargo along microtubules to the nucleus [73]. Exactly how PCV2 recruits the host 
machinery is unclear, however, the viral Cap protein has been shown to play a vital role 
in the translocation process. Specifically, the Cap protein induces acetylation of 
microtubular α-tubulin [74] and interacts directly with the Intermediate Chain 1 (IC1) 
subunit of dynein via residues 42-100 of the Cap protein following disassembly and 
release from early endosomes [73]. Inhibition of dynein activity, knockdown of the IC1 
subunit, and disruption of the microtubular network were all individually found to 
significantly decrease PCV2 replication without affecting internalization and endosomal 
uptake of the virions [73].  
Upon nuclear entry, VLPs aggregated into non-membrane bound intranuclear 
inclusion bodies often in close proximity to networks of protein-like structures [71]. It is 
believed that following replication, these protein networks are involved in the 
encapsidation of immature virions near the nuclear periphery prior to release back into 
the cytoplasm [71]. During this second cytoplasmic phase, double-membrane and triple-
membrane bound intracytoplasmic inclusion bodies or viral factories containing VLPs 
appear with the assistance of organelle membranes such as the Golgi complex and rough 
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endoplasmic reticulum, indicating a potential role of these organelles in the final stages of 
viral assembly [71]. Three possible mechanisms of cellular release have been observed 
for mature PCV2 virions: 1) VLPs move as a unit within inclusion bodies utilizing 
organelle membranes to the plasma membrane for release via budding, 2) PCV2 particles 
are released from cytoplasmic inclusion bodies and exit the cell through exocytosis, or 3) 
complex cytoplasmic inclusion bodies are formed with various subcellular irregularities 
leading to cell lysis and release of PCV2 progeny [71].  
The goal and conditional requirements of PCV2 depend on the type of cell 
infected. Inhibition of endosome acidification was shown to reduce PCV2 infection in 
monocytic cells [69], but enhance PCV2 infection and replication in epithelial cells [75]. 
This discrepancy in optimal pH may indicate that different proteases are involved in the 
disassembly of PCV2 in epithelial and monocytic cells [67]. Furthermore, despite prolific 
infection of monocytic cells, PCV2 replication was found to only occur within the nuclei 
of epithelial and endothelial cells [76-78].  The reason behind this is believed to be due to 
the virus’s reliance on host cell machinery and mitosis for replication since the viral 
genome does not encode its own replicative tools and is unable to autonomously 
penetrate the nuclear envelope [79]. PCV2 can only achieve nuclear entry at the end of 
mitosis when it is incorporated into the nuclei of daughter cells, after which, it must wait 
until the cell enters S-phase to hijack host replicative machinery for replication [79]. As a 
result, PCV2 likely depends on cells with higher mitotic rates for adequate replication. 
Although monocytic cells are not primary sites of viral replication, they are still 
main targets of PCV2. Monocytic cells are an essential component of innate immunity, 
but also play an important role in initiating adaptive immunity. Specifically, dendritic 
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cells (DCs) and macrophages engulf antigens at the site of infection, release cytokines 
that enhance the immune response, and then travel to lymph tissues where they present 
these processed antigens via surface proteins to activate general and pathogen-specific T 
lymphocytes. PCV2 is believed to have immunosuppressive capacity as indicated by the 
presence of lymphoid depletion, lesions, and susceptibility to secondary infection. 
Immunomodulation of monocytic cells may represent a potential mechanism of PCV2-
induced immunosuppression by compromising a vital link between the innate and 
adaptive immune response to PCV2 and other pathogens.  
The ability of PCV2 to accumulate to such high levels in the cytoplasm of 
monocytic cells without viral replication indicates inadequate degradation of the virus 
following internalization [80]. However, this increase in cytoplasmic PCV2 does not 
correspond with increased cell death. Vincent et al. (2003) found that PCV2 was able to 
persist within myeloid dendritic cells (DCs), following in vitro inoculation, without 
losing infectivity or inducing cell death. They also found no evidence of surface protein 
modulation in infected DCs or viral transmission to activated T-lymphocytes [78]. A 
similar result was observed in alveolar macrophages (AM); however, the apoptotic rate 
was lower in infected AMs compared to controls [81]. It is believed that the silent and 
persistent infection of myeloid DCs and capacity to escape degradation in various 
monocytic cells may represent a mechanism of PCV2 immune evasion essential for 
sustained infection [78, 80]. It has also been proposed that PCV2 utilizes monocytic cells 
for systemic dissemination by taking advantage of their normal circulation throughout the 
body [64, 78]. Therefore, survival of infected monocytic cells may be imperative for 
adequate viral spread and systemic infection.  
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Even though PCV2 caused no observable modulation to myeloid DCs, it does 
possess immunomodulatory capacity in other types of DCs. Vincent et al. (2005) assessed 
PCV2 interactions with a variety of DC subsets, including DC precursors, myeloid DCs, 
conventional blood DCs, and plasmacytoid DCs[82]. Once again, no modulation in 
myeloid DC antigen presentation or maturation was observed in the presence of PCV2. 
However, PCV2 infection of plasmacytoid DCs, also known as natural interferon-
producing cells (NIPCs), was found to interrupt a normal costimulatory function required 
for myeloid DC maturation in vivo by inhibiting NIPC production of IFN-alpha and TNF-
alpha following interaction with CpG-oligonucleotides (CpG-ODNs). The exact manner 
in which PCV2 disrupts production of these cytokines is unknown, but discovery of 
stimulatory and inhibitory CpG motifs within the PCV2 genome may provide some 
explanation [83]. One motif in particular was found to inhibit the production of IFN-
alpha via TLR9 signaling in porcine PBMCs even in the presence of other stimulatory 
CpG motifs from the PCV2 genome [83, 84]. However, in a subsequent study the 
inhibitory effect of PCV2 was found to not only target CpG-ODN-induced cytokines, but 
responses induced by TLR7 and TLR9 agonists as well as other viral pathogens [85]. 
Also PCV2 DNA and CpG-ODNs did not co-localize within NIPCs during this study, 
suggesting they target distinct receptors. Therefore, PCV2 may modulate NIPCs via 
unique mechanism to disrupt both autocrine and paracrine maturation of myeloid DCs, 
impairing the ability of the host to recognize and respond to simultaneous or secondary 
infections [80, 85].  
PCV2 has also demonstrated immunomodulatory capacity in alveolar 
macrophages (AMs). Chang et al. (2006) found that infected AMs exhibited reduced 
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phagocytosis and microbicidal capacity leaving the host vulnerable to secondary lung 
infections. The decreased microbicidal capacity is believed to be due in part to impaired 
production of reactive oxygen species (ROS) and may illustrate a potential mechanism 
utilized by PCV2 to escape degradation within these cells [81]. The infected AMs also 
exhibited increased production of cytokines and chemokines involved in enhancing the 
inflammatory response and recruiting polymorphonuclear leukocytes (PMNs) and 
monocytes to the infection site, such as TNF-alpha, AMCF-II, IL-8, MCP-1, and G-CSF 
[81]. Increased expression of these immune signals have also been observed in lymphoid 
tissues of PMWS-affected pigs [25, 86, 87], indicating modulation of monocytic cytokine 
and chemokine production may contribute to lesion formation by recruiting acute phase 
inflammatory cells and other monocytic cells to PCV2-infected tissues [81]. 
Furthermore, there is a correlation between increased levels of PCV2 in lymphoid 
organs of naturally PMWS-affected pigs and lymphocyte depletion and histiocytic lesions 
resulting from monocyte infiltration [88]. Darwich et al. (2002) found that the levels of 
CD8+ (cytotoxic) and CD4+CD8+ (double positive) T-cells were significantly decreased 
in PCV2-positive animals compared to PCV2-negative and healthy controls. 
Additionally, the magnitude of lymphocyte depletion and reduction in levels of CD8+ T 
cells and IgM+ B cells in peripheral blood were found to correspond with the level of 
PCV2 antigen in lymphoid tissues [89]. The mechanisms behind PCV2-induced 
lymphocyte depletion remain speculative. As reviewed by Darwich and Mateu (2012) 
and X.J. Meng (2013), some studies suggest that apoptosis may be a prominent 
mechanism leading to lymphocyte depletion while others provide evidence implicating 
reduced proliferation rather than apoptosis as the root source.  
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Whether these depletion mechanisms are induced directly by the virus or 
cytokines is also highly debated. Studies have shown damage due to PCV2 replication 
can directly deplete B and T lymphocytes [90, 91]. However, cytokine imbalances and 
alterations have been observed in many lymphoid organs of PMWS affected animals as 
well [87]. Specifically, levels of IL-10 have been associated with disease severity and 
viral load [92, 93] and over expression of IL-10 mRNA in the thymus was found to 
correlate with the degree of lymphocyte depletion and thymic atrophy [87]. PCV2 has 
been shown to induce similar alterations in vitro by increasing production of IL-10 and 
other pro-inflammatory cytokines and suppressing production of IL-2 and IL-4 by 
PBMCs collected from both PMWS-affected and healthy pigs as well as repressing IL-2, 
IL-4, and IFN-y production by PBMCs from PMWS-affected pigs compared to healthy 
pigs in response to mitogen or superantigen stimulation [86, 94]. Therefore, it is unclear 
whether these cytokine imbalances in vivo are caused by PCV2 modulation of infiltrating 
monocytes that actually induce depletion or if they are simply a reactive response 
resulting from depletion via direct viral-induced mechanisms.   
 
Factors Affecting PCV2 Virulence, Pathogenesis, and Disease Progression 
 There is significant variation in the virulence of PCV2 isolates, such that simply 
being infected with PCV2 does not mean subsequent clinical manifestation of PCVAD. 
Assessing virulence is further complicated by the fact that experimental infection with a 
PCV2 isolate alone, regardless of its virulence in naturally infected herds, often results in 
subclinical infection and rarely in disease [15, 30]. As a result, the virulence of PCV2 
isolates is generally quantified based on the level of PCV2 replication and histological 
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changes rather than symptomatic status [14]. There are four major factors believed to 
influence virulence and related pathogenesis: virus-dependent, host-dependent, secondary 
infection, and modulation of innate and adaptive immunity [20]. Since multiple external 
factors are presumed to be involved, obtaining consistent findings on isolate virulence 
and identifying regions of the PCV2 genome associated with increased virulence has 
proven difficult.  
 
a) Virus-Dependent: Variation in Strain Virulence 
Grau-Roma et al. (2008) isolated PCV2 from sera of pigs from PMWS affected 
farms and non-PMWS affected farms in Spain. They compared the ORF2 sequences of 
the 87 isolates and found they could be divided into two different genotypic groups 
corresponding to PCV2b (genotype 1) and PCV2a (genotype 2). PCV2b strains were 
detected exclusively in PMWS affected farms while PCV2a strains could be found in 
both affected and non-affected farms with several pigs from affected farms infected with 
both PCV2b and PCV2a strains [15]. Similar reports were made in North America, with 
the PCV2 strains isolated from diseased pigs exhibiting high sequence similarity with 
PCV2b isolates from Europe and Asia [56, 95]. However, there were also reports that 
contradicted these findings. Phylogenetic analysis of 70 PCV2 strains, including 34 
strains isolated from pigs with a variety of clinical conditions, found that strains 
associated with PMWS were dispersed throughout the phylogenetic tree and often 
grouped with strains associated with other diseases and healthy pigs [43]. Experimental 
infection of 113 pigs with one of four different PCV2 isolates, two PCV2a and two 
PCV2b isolates, showed no difference in virulence between genotypic groups, however, 
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differences within genotypic groups were observed [96]. Dual inoculation of 20 germ-
free pigs 7 days apart with PCV2a and PCV2b (2a|2b or 2b|2a), PCV2b (2b|2b), or 
PCV2a (2a|2a) showed that heterologous inoculation resulted in increased severity and 
incidence of disease compared to inoculation with PCV2a or PCV2b alone [97]. This 
indicates that co-infection with PCV2a and PCV2b leads to increased virulence compared 
to singular infection and may explain the elevated pathogenicity observed with the 
emergence of PCV2b since majority of herds were already infected with PCV2a [8, 14, 
97]. 
Additionally, PCV2a strains have also been associated with clinical symptoms 
and exhibit variation in virulence. Opriessnig et al. (2006b) experimentally infected 42 
specific-pathogen-free (SPF) pigs with a PCV2a strain isolated from a pig with no PCV2-
associated lesions (PCV2-4838) and a PCV2a strain isolated from a pig with PCV2-
associated lesions and disease symptoms (PCV2-40895). Sequence comparison revealed 
a total of 20 nucleotide differences between the two strains: 5 in ORF1, 14 in ORF2, and 
one in ORF3 resulting in 99.4%, 96.1%, and 99.7% amino acid sequence homologies, 
respectively. They found significant evidence based on severity of microscopic lesions 
and level of PCV2 and antibodies in serum that the PCV2-40895 isolate was more 
virulent than the PCV2-4838 isolate, indicating that PCV2a can be pathogenic and 
variation in virulence between even genetically similar isolates exists [9].  
The occurrence of novel strains with increased virulence pose a constant threat 
due to the high mutation rate of PCV2 [49]. Majority of genetic differences between 
strains present today are located within ORF2, occasionally altering the amino acid 
sequence of the capsid protein. Additionally, the ORF2 sequences of PCV2a strains were 
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found to be more variable than PCV2b strains, indicating PCV2b may represent the 
evolution of PCV2a towards increased virulence [15, 96, 98]. In fact, comparison 
between archival PCV2 strains from 1970-1971 and contemporary PCV2 strains 
uncovered a consistent 9bp sequence difference in an immunogenic epitope of ORF2, 
altering configuration of the nucleocapsid from hydrophilic in archival strains to 
hydrophobic in contemporary strains [99]. Experimental infection of gnotobiotic pigs 
with PCV2 clones illustrated that the archival PCV2 strains were avirulent compared to 
contemporary PCV2 strains [99].  Additional support for the role of Cap sequence 
variation in isolate pathogenicity is given by several studies that illustrate as few as one 
or two amino acid substitutions in the Cap protein is sufficient to cause alterations in 
PCV2 virulence [100-102]. Thus, comparison of ORF2 sequences between current PCV2 
isolates has been a major area of focus in attempt to identify specific regions associated 
with virulence.  
Larochelle et al. (2002) identified three different regions of the Cap protein with 
increased amino acid heterogeneity, positions 59-80, 121-136, and 180-191 [43]. Two of 
these regions overlap with dominant immunoreactive areas at positions 65-87 and 113-
147 previously identified using Pepscan [103]. In fact, majority of differences between 
isolates from healthy and diseased pigs are located within immunogenic epitopes of the 
Cap protein [30, 45]. However, after further analysis no consistent amino acid motifs 
within these regions were found that could be associated with PCV2 isolates from pigs 
with PMWS or other disease symptoms [43]. In another study, Grau-Roma et al. (2008) 
identified three similar regions of high heterogeneity between ORF2 sequences at amino 
acid positions 57-91, 121-136, and 185-191. Alignment revealed amino acid sequence 
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patterns in these regions that were specific to either PCV2a or PCV2b. As previously 
stated, the PCV2a sequences were more variable within these regions while the PCV2b 
sequences were more conserved between isolates. Once again they were unable to detect 
any association between the PCV2b sequence found in individual pigs and disease status 
[15]. Similar outcomes were also reported following phylogenetic analyses of Dutch [53] 
and French isolates [98]. This recurrent inability to identify genetic signatures of PCV2 
virulence suggests that external factors have significant influence over virulence and the 
outcome of infection.   
 
b) Innate and Adaptive Immunity in PCV2 Infection 
PCV2 infection has been shown to induce a humoral immune response, a facet of 
adaptive immunity illustrated by antibody production, which in subclinically infected 
pigs results in decreased viral titers [65, 88, 104]. Generally, specific IgM antibodies are 
the first to appear in serum and represent recent or on-going infection, while specific IgG 
antibodies are detected later on and represent the animals immune status for a particular 
pathogen, such as prior exposure or vaccination. Progranichnyy et al. (2000) intranasally 
and intramuscularly inoculated five 8-week old colostrum deprived pigs free of any major 
swine pathogens with a strain of PCV2 isolated from a pig diagnosed with PMWS. PCV2 
viremia could be detected at 7, 14, and 21 dpi, but not at 28 dpi. PCV2-specific 
antibodies were first detected at 14 dpi, however, the presence of PCV2-neutralizing 
antibodies was not observed until 28 dpi [104]. A similar result was obtained by McKnite 
et al. (2014), with PCV2-specific IgM antibodies present at 14 dpi, peaking at 21 dpi and 
dropping again at 28 dpi and PCV2-specific IgG or neutralizing antibodies present at 21 
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dpi followed by an increase in levels at 28 dpi. Although viremia was still detected at 28 
dpi in this study, it had significantly decreased in level compared to 14 and 21 dpi [65]. 
In fact, a positive phenotypic correlation was found between overall viral load and IgM 
(r=0.26 to 0.34, 14-28 dpi, P<0.0001) and IgG (r=0.17 to 0.20, 21-28 dpi, P<0.01) during 
the challenge [65]. However, variation in the level and type of adaptive immunity 
between animals has been observed and may play a significant role in the efficacy of 
PCV2 replication and virulence.  
Meerts et al. (2005) infected 12 gnotobiotic pigs with PCV2 and treated 4 of these 
pigs with cyclosporine A (CysA) in order to assess the influence of adaptive immunity on 
PCV2 replication. All CysA treated pigs had higher viral titers compared to the non-
CysA treated pigs, suggesting adaptive immunity plays a central role in limiting viral 
replication [88]. They also observed several different replication and antibody profiles 
among the non-CysA treated pigs. No PCV2 could be detected in the two pigs with the 
highest neutralizing antibody titers present at 15 dpi along with a significant increase in 
IFN-y mRNA at 15 dpi. Five pigs with lower neutralizing antibody titers and no 
detectable increase in IFN-y, had low to moderate PCV2 titers at 15 dpi that either 
plateaued or decreased as time progressed. A single pig exhibited no neutralizing 
antibodies or rise in IFN-y and had a low PCV2 titer at 15 dpi that drastically increased at 
21 dpi. Since a higher level of viral replication is associated with increased potential of 
disease progression, this study suggests that the outcome of infection may be partially 
contingent upon the adaptive immune response of the host [88].  
Meerts et al. (2006) went on to further investigate the correlation between viral 
replication and lack of neutralizing antibodies in a subsequent study comparing 
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experimentally infected SPF pigs, naturally PMWS-affected pigs, and healthy controls. 
No PCV2-neutralizing antibodies were found in the naturally infected PMWS-affected 
pigs and only low neutralizing antibody titers could be observed between 7 and 14 dpi in 
the experimentally infected PMWS-affected pigs. This differed from the healthy and 
subclinically infected pigs, which exhibited neutralizing antibody titers corresponding 
with that of total antibodies [105]. They also found that the IgM profiles differed between 
healthy and affected pigs, with IgM increasing throughout the study in 
healthy/subclinically infected pigs and decreasing or remaining at low levels in affected 
pigs [105]. A similar result was found by Fort et al. (2007), such that PMWS-affected 
pigs had negative or significantly lower neutralizing antibody titers than healthy animals 
and a suggestive inverse correlation between neutralizing antibody titers and viral load. 
In addition, PCV2-specific IgG titers were positively correlated with neutralizing 
antibody titers (r=0.76, P<0.0001), while no correlation was observed between IgM and 
neutralizing antibody titers [106]. Together, these studies illustrate that there is a 
difference in the humoral response between subclinically infected pigs and clinically 
affected pigs with the level of viral replication and incidence of disease increasing in the 
absence of PCV2-neutralizing antibodies [88, 105, 106]. Whether these differences in 
adaptive immunity are simply due to variation in host immune responses or variation in 
efficacy of PCV2 immunomodulation between hosts is still unclear.  
Natural mechanisms of active and passive immunity have also been shown to 
decrease host susceptibility to PCV2, including prior PCV2 infection [96] and PCV2-
specific maternal antibodies [107, 108]. In the second part of the study conducted by 
Opriessnig et al. (2008), they initially inoculated pigs with either a PCV2a or PCV2b 
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isolate then re-inoculated the animals 5 weeks later with the other isolate and compared 
the responses to pigs without prior exposure. Viral replication of the secondary isolate 
was almost completely blocked in the re-inoculated pigs, indicating prior infection not 
only provided protection against subsequent infection by way of active immunity, but 
that cross-protection between PCV2a and PCV2b isolates also exists [96]. Several studies 
have also noted a potential litter effect for PMWS susceptibility and mortality [107, 109]. 
It is known that newborn piglets are protected by passively acquired maternal antibodies 
from a variety of viral pathogens [108]. Therefore, sow infection or vaccination status 
and as a result maternal antibody titer have also been associated with piglet disease 
susceptibility.  
McKeown et al. (2005) experimentally infected 24 piglets split into 4 groups 
based on maternal antibody titer at 12 days of age: group A were negative, group B had 
low levels, and groups C and D had high levels of maternal antibodies. Groups A, B, and 
C were inoculated at day 0 with PCV2 and then re-infected at day 42. Group D was only 
infected at day 42. Viremia prior to day 42 was detected in nearly all group A and B 
piglets, but in only 2 of 8 group C piglets. Following re-infection or initial inoculation 
(group D) at day 42, viremia was observed between 7 and 21 dpi in nearly all group A, B, 
and D piglets, but only 3 of 8 group C piglets [108]. All groups except for group C tested 
negative for PCV2 maternal antibodies at day 42 [108]. Sow antibody titer was also 
associated with piglet mortality in naturally PMWS-affected farms, such that the piglets 
from sows with medium to high antibody titers had significantly lower death percentages 
than those from sows with low antibody titers [107]. These results indicate that higher 
titers of PCV2 maternal antibodies provides greater protection against early PCV2 
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infection and that a combination of high PCV2 maternal antibody titer and prior exposure 
to PCV2 decrease susceptibility to secondary PCV2 infection by extending the length of 
protection supplied by the maternal antibodies [108].  
 
c) Immunostimulation and Secondary Infections in PCVAD 
 Coinfection with secondary pathogens or extraneous immunostimulation with 
adjuvants or vaccines have been shown to fuel the development and severity of PCVAD 
[30]. These factors are often required for PCV2 infected animals to display clinical 
symptoms, which has led many to question if PCV2 is actually the etiological agent 
behind these diseases. The widespread infection of PCV2 in even asymptomatic herds 
and variation in PCVAD symptoms further complicated its discovery and association 
with disease [110]. Studies have revealed that although PCV2 alone often results in 
subclinical infection, it is the common and crucial component of PCVAD development 
[20, 111].  
 In 2004, Opriessnig et al. (2004b) assessed the effect of dual infection with 
Mycoplasma hyopneumoniae and PCV2 on development of PMWS. They randomly 
assigned 67 pigs to 4 groups consisting of a control group (n=17), a M. hyopneumoniae 
group (n=17), a PCV2 group (n=16), and a dual M. hyopneumoniae/PCV2 group (n=17). 
The pigs were inoculated with M. hyopneumoniae at 4 weeks of age and/or PCV2 at 6 
weeks of age. The dual-infected pigs presented with reduced weight gain, labored 
breathing, and lethargy. Compared to the other groups, the dual-infected pigs had 
significantly more severe macroscopic lung lesions, microscopic PCV2-associated lung 
and lymphoid lesions, and increased amounts of PCV2-antigens associated with the 
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lesions. Four of the 17 dual-infected pigs also had symptoms characteristic with PMWS 
such as severe lymphoid depletion, reduced growth rate, and granulomatous 
lymphadenitis associated with high levels of PCV2-antigen. These findings, indicate that 
M. hyopneumoniae exacerbates PCV2-associated lung and lymphoid lesion severity and 
promotes increased and sustained levels of PCV2 antigen leading to increased incidence 
of PMWS [17].  
 In 2002, pigs with systemic PCVAD were assessed for pathogens and it was 
found that M. hyopneumoniae was detected in 36% of the 484 cases, whereas singular 
PCV2 infection was detected in only 2% of cases [112]. Other common pathogens that 
were associated with PCV2 coinfection in this study included Porcine Reproductive and 
Respiratory Syndrome Virus (PRRSV) found in 52% of cases, bacterial septicemia or 
pneumonia in 22% of cases, and Swine Influenza Virus (SIV) in 5.4% of cases [112]. 
Based on these findings, it is common opinion that there is no secondary pathogen that is 
solely responsible for inducing incidence and severity of PCV2-associated diseases [20]. 
Rather, it is believed several pathogens that vary from location to location are capable of 
eliciting PCVAD development [20].  
 Experimental infection of gnotobiotic pigs with PCV2 alone generates only 
subclinical to mild symptoms with little dissemination of viral antigen, however, when 
gnotobiotic pigs are co-infected with PCV2 and porcine parvovirus (PPV) they present 
with moderate to severe symptoms and widespread dissemination of PCV2 antigen in 
lymphoid tissues and histiocytic lesions [113]. Since experimental infection of 
conventional pigs with PCV2 has been occasionally successful at inducing PMWS 
symptoms, but a secondary pathogen is required to elicit disease symptoms in gnotobiotic 
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pigs, Krakowka et al. (2001) proposed that increased PCV2 replication and dissemination 
in vivo requires immune stimulation mediated by monocytic cell activation in lymphoid 
tissues. To test this hypothesis, they performed a short-term experiment to assess the 
effect of local immunostimulation on viral replication and dissemination and a long-term 
experiment to assess the effect of systemic immunostimulation on incidence of PMWS 
[110]. 
 For the short-term experiment, Krakowka et al. (2001) inoculated 7 piglets with 
PCV2 at 1 day of age. At 3 and 7 days of age, piglets were injected in the left hip and 
shoulder with either the immunostimulant keyhole limpet hemocyanin (KLH), an 
irrelevant antigen, emulsified in incomplete Freund’s adjuvant (ICFA) or KLH in saline. 
Viral load was then assessed at 13-14 dpi in local lymph nodes draining injection sites 
and contralateral lymph nodes, so that each pig served as its own control. The amount of 
recovered infectious virus was highest in draining lymph nodes of KLH/ICFA injection 
sites compared to contralateral lymph nodes and compared to pigs injected with KLH in 
saline. Furthermore, PCV2 was found in distal lymph nodes of animals injected with 
KLH/ICFA, but only sparsely distributed in distal lymph nodes of animals injected with 
KHL in saline. For the long-term experiment, they inoculated 10 piglets at 1 day of age 
with PCV2. At 3 and 7 days of age, piglets were injected in both hips and shoulders to 
achieve systemic immunostimulation with either KHL/ICFA alone or KHL/ICFA 
followed by intraperitoneal (IP) injections of thioglycollate broth (glycan) at 10 and 20 
days of age to stimulate peritoneal macrophages. All immunized pigs (both KLH/ICFA 
and KLH/ICFA-IP glycan) infected with PCV2 developed PMWS by 35 days of age 
while none of the infected pigs that were not immunized developed PMWS. Through 
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these experiments, Krakowka et al. (2001) illustrated that immunostimulation enhanced 
PCV2 replication in local lymph nodes as well dissemination to distal lymphoid tissues 
and that systemic immunostimulation, with or without macrophage activation, triggered 
the development of PMWS in PCV2-infected gnotobiotic pigs, indicating that immune 
activation is essential for PCV2 pathogenesis [110].  
 Immunostimulation by way of vaccination or adjuvant administration increases 
lymphocyte proliferation [114]. This mechanism could explain the correlation between 
increased viral antigen and immunostimulation since PCV2 replication may increase in 
dividing cells. However, another study assessing the effects of immunostimulation on 
PMWS development in SPF piglets did not find any difference in incidence or severity of 
disease between piglets that had been subjected to the immunizing agent, KLH/ICFA, 
and those that had not, suggesting immunostimulation is not an important factor in 
PMWS development [115]. In 2005, a reverse transcription PCR (RT-PCR) assay able to 
detect the presence of PCV2 capsid mRNA was developed and allowed the researchers to 
be able to discern between replicating PCV2 and PCV2 virions within PK-15 cells [116]. 
This knowledge was used in subsequent studies to quantify the amount of Cap mRNA 
within PBMCs using a quantitative real time PCR (qPCR) assay in order to better assess 
the impact of immunostimulation [114, 117].  
In vitro inoculation with PCV2 showed that viral replication was significantly 
increased in PBMCs that had been stimulated with concanavalin A (ConA) compared to 
resting PBMCs [117]. However, the magnitude of increase in viral replication within 
stimulated PBMCs was later found to depend on the mitogen used and independent of 
cell proliferation since similar levels of Cap mRNA were found in proliferating and non-
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proliferating cells [114]. Interestingly, they also found that PCV2 infected PBMCs 
stimulated with pokeweed mitogen (PWM) exhibited increased apoptosis compared to 
uninfected or unstimulated infected PBMCs. In fact, PBMCs infected with PCV2 alone 
without stimulation exhibited reduced levels of apoptosis compared to non-infected 
PBMCs [114]. These findings indicate that immunostimulation increases PCV2 
replication, supporting the in vivo study conducted by Krakowka et al. (2001). However, 
the mechanism that induces this replication appears to be independent of lymphocyte 
proliferation [114]. In addition, certain stimulation increased apoptosis compared to 
infection alone [114]. Although this has not yet been tested in vivo, it may indicate that 
immunostimulation plays an even greater role in PCV2 pathogenesis than originally 
thought.   
The question of whether PCV2 immunosuppression enables secondary infections 
that exacerbate disease symptoms or secondary infections stimulate PCV2 replication and 
pathogenesis is analogous to the age old question of what came first: the chicken or the 
egg? The answer seems to change depending on the angle from which you view it. The 
illustrated importance of immunostimulation and wide variety of secondary pathogens 
capable of eliciting PCVAD symptoms suggest that secondary infections may simply 
provide the required stimulation of the immune system to enhance PCV2 pathogenesis. In 
this case, pathogenesis would not be contingent upon a specific secondary pathogen, but 
on the type of stimulation provided by that secondary infection. Immunosuppression was 
also shown to promote PCV2 replication and spread, however, when a stronger 
immunosuppressant was used, characteristic PCVAD inflammatory reactions were not 
observed [118, 119]. Therefore, the degree of immunosuppression, immunostimulation, 
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and time of secondary infection may all contribute to the pathogenic outcome of PCV2 
infection.  
 
d) Host-Dependent: Role of Host Genetics in PCV2 Susceptibility 
 Although PCV2 infection is widespread amongst all pigs, the progression from 
subclinical infection to PCVAD has been shown to vary between breeds and individuals. 
This indicates that genetic variation between breeds, populations, and individuals may 
play a significant role in host susceptibility to PCV2 infection and subsequent incidence 
and severity of disease.  
 Opriessnig et al. (2006a) compared the susceptibility of three different breeds of 
pigs to PCV2 infection. In this study, they selected 75 colostrum fed, purebred female 
pigs raised under identical conditions from a single farm consisting of Duroc (n=26), 
Landrace (n=25), and Large White (n=24). Twelve of these pigs (3 Duroc, 6 Landrace, 
and 3 Large White) were mock inoculated and the remaining 63 pigs (23 Duroc, 19 
Landrace, and 21 Large White) were experimentally infected intramuscularly and 
intranasally with PCV2 at 5-7 weeks of age. The control pigs were kept together in a 
room separate from the infected pigs. Clinical evaluation was conducted daily while 
weights and serum samples were collected 7, 14, 21, 28, and 35 dpi. Half of the infected 
and control pigs from each breed were necropsied at 21 dpi and the other half at 35 dpi. 
Similar macroscopic and microscopic lesions including enlarged lymph nodes, 
granulomatous inflammation, and lymphoid depletion were observed in all 3 breeds. 
However, lymphoid depletion was significantly more severe in Landrace compared to 
Duroc and Large White. Additionally, 3 of the 19 Landrace pigs developed severe 
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lymphoid lesions containing high levels of PCV2 antigen, which are characteristic of 
PMWS. None of the Duroc or Large White individuals exhibited such lesions. Therefore, 
the 3 breeds were determined to be equally susceptible to subclinical PCV2 infection, but 
Landrace were more susceptible to developing clinical PMWS [120].  
 In a subsequent study, Opriessnig et al. (2009) went on to compare susceptibility 
of Landrace and Pietrain pigs to PCV2. Together they had 39 Landrace and 39 Pietrain 
pigs that were divided into 4 groups: Landrace non-inoculated negative control (n=13), 
Pietrain non-inoculated negative control (n=13), Landrace-PCV2 (n=26), and Pietrain-
PCV2 (n=26). The Landrace-PCV2 and Pietrain-PCV2 groups were inoculated with 
PCV2 at 21 weeks of age and blood samples were collected weekly for 3 weeks post 
infection. Serum samples were tested for PCV2-specific IgG and IgM antibodies, 
neutralizing antibodies, and PCV2 viremia. Plasma samples were tested for certain 
cytokines. All groups of pigs were necropsied at 21 dpi. Clinical disease was not 
observed in any of the animals and the presence of macroscopic lesions did not differ 
between breeds. No differences in PCV2-specific IgG and IgM levels, neutralizing 
antibodies, viremia, or cytokine concentrations were observed between breeds. Both 
PCV2 groups had significantly more severe lesion scores than the control groups, but the 
Pietrain-PCV2 group had significantly less severe microscopic lesions than the Landrace-
PCV2 group. Only about 34.6% of the Pietrain-PCV2 group had mild follicular depletion 
in lymph nodes along with a low level of PCV2 antigen while the remaining 65.4% 
exhibited normal lymphoid tissues. On the other hand, 30.7% of the Landrace-PCV2 
group exhibited moderate to severe lymphoid depletion and histiocytic replacement along 
with moderate lymphohistiocytic infiltration of the heart and liver tissues. These results 
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indicate that there is a difference in susceptibility to PCV2-associated lesions between 
Landrace and Pietrain pigs [121], supporting their previous findings suggesting a genetic 
component to PCVAD susceptibility [120]. 
 In 2005, Rose et al. conducted a study in France to assess the presumed protective 
effect of the Pietrain breed against PMWS. They selected 4 PMWS-affected farms in 
France and randomly inseminated sows with either pure Pietrain semen or non-Pietrain 
semen normally used on the farm (semen X). One of the farms had a third genetic type of 
semen (Y) that was used in addition to the Pietrain and X semen. This experiment was 
carried out in 2 batches per farm for a total of 8 batches. A total of 30 pigs per paternal 
genetic group stratified by litter (n=2) were selected from each batch. This resource 
population of 540 piglets were then housed in identical conditions, observed for clinical 
symptoms, and weighed from birth to slaughter. Blood samples were taken at age of 
weaning, 7, 13, 16, and 21 weeks of age and then again at slaughter and tested for PCV2-
specific antibodies. A portion of the resource population that exhibited the best growth 
performance and assumed to be unaffected by significant disease were selected as a 
reference group used to account for inherent differences in growth performance between 
genetic groups. The average incidence rate of PMWS was 18% with no significant 
differences in age of onset or morbidity between the paternal genetic groups [21]. 
However, the time it took for PMWS to develop was found to be influenced by PCV2 
seroconversion and associated with maternally acquired passive immunity [21], 
corroborating the impact of maternal effects on PMWS incidence and survival [107, 108]. 
Therefore, the inability to detect a significant paternal genetic effect in this study may 
have been due in part to confounding maternal effects. Taking this into account, the 
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observed difference in morbidity between Pietrain-derived and X-derived offspring, 
16.3% and 17.3% respectively, may indicate a genetic source of reduced PMWS 
susceptibility in the Pietrain breed [21].  
To further investigate the effect of host genetics on PCVAD progression, 
McKnite et al. (2014) performed the first genome wide association study (GWAS) to 
identify genomic regions associated with PCV2 susceptibility. The resource population 
was comprised of 4 batches of crossbred pigs derived from various commercial lines 
(Nebraska Index Line (NIL), Landrace, Large White, and Duroc). A total of 386 pigs 
across the batches were experimentally infected intranasally and intramuscularly at 5 
weeks of age with PCV2b and were weighed and monitored for clinical symptoms. Blood 
samples were taken weekly over the course of the 28-day challenge to assess for PCV2 
specific IgM and IgG antibodies and PCV2 viremia. All pigs were genotyped for 
approximately 61,177 SNPs using the Illumina Porcine SNP60 BeadArray. After filtering 
to remove low quality SNPs and DNA samples, a total of 370 samples and 56,433 SNPs 
were used for GWAS. Using a Bayes B model, SNP effects were measured in 1Mb 
windows and then combined to get the proportion of genetic variance for each indicator 
trait of PCVAD susceptibility: weekly viremia, PCV2-specific IgG and IgM antibody 
levels, and Average Daily Gain (ADG) as well as overall viral load and ADG. Host 
genetics was found to explain significant proportions of phenotypic variation for both 
viremia (35-59%) and PCV2-specific antibody levels (10-59%), however, the proportion 
varied across weekly measurements. In addition, multiple loci (1Mb windows) were 
found to contribute to the phenotypic variation for each of the target traits, with some 
unique to specific traits and common between traits. Specifically, windows on SSC1, 
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SSC7, and SSC12 affected viral load and/or specific weekly viremia measurements while 
windows on SSC12, SSC14, and SSCX affected weekly IgM and IgG [65].  
McKnite et al. (2014) hypothesized that loci influencing viral replication and 
accumulation would indirectly affect the immune response and weight gain of individuals 
over the course of the PCV2 challenge. They assessed genomic correlations between 
PCVAD indicator traits and found that viral load had a significant negative genomic 
correlation with ADG (r=-0.21 to -0.24, 0-14 dpi, P<0.0001) and positive genomic 
correlation with IgM (r=0.22 to 0.54, 14-28 dpi, P<0.0001) and IgG (r=0.29 to 0.43, 21-
28 dpi, P<0.0001). Single marker association was performed using 31 SNPs with 
significant effects on viral load to estimate pleiotropic effects across the indicator traits 
[65]. Of these SNPs, 41.9% had effects on two or more measurements of weekly viremia, 
35.5% had effects on overall ADG or at least one measurement of weekly ADG, 16.1% 
had effects on one or more measurements of IgM, and 19.4% had effects on one or more 
measurements of IgG [65]. In addition, the combined effect of 3 SNPs located on SSC9 
and SSC12 that captured the negative relationship between viral load and ADG indicated 
that individuals with more favorable alleles at these loci would have lower weekly 
viremia and viral load and higher weekly and overall ADG [65].  
This study was expanded with the incorporation of additional maternal lines from 
North-American swine breeding programs, which doubled the amount of samples 
(n=974) used in the GWAS [122]. Following the same protocols as described in McKnite 
et al. (2014), this study found that the SNP genotypes explained a larger proportion of 
phenotypic variation for overall viral load (64%) than detected by the previous study 
[122]. Additionally, they uncovered two major SNPs on SSC12 and SSC7 that explained 
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11.5% and 2.8% respectively of the genetic variation for viral load [122].  Although, the 
proportion of phenotypic variation in ADG explained by the SNP genotypes was still 
limited, there was once again a negative correlation between viral load and overall ADG 
(r=-0.36, P <0.0001), partially explained by the major SNPs. Specifically, animals with 
the CC genotype for the major SSC12 SNP, exhibited lower viral load (P<0.0001) and 
higher overall ADG (P<0.05) compared to the heterozygous (CT) or alternate 
homozygous (TT) genotypes [122].  
 Building on the findings of McKnite et al. (2014) and Engle et al. (2014), a 
subsequent study went on to assess the role of host genetics in the level of the pro-
inflammatory cytokine, TNF-alpha, known to be modulated in PCV2 infected animals 
[123]. Initially, the protein serum TNF-alpha levels were measured weekly in 6 pigs with 
high viral load and low ADG and 6 pigs with low viral load and high ADG. A significant 
difference in TNF-alpha level at 21 dpi was observed between the two groups. TNF-alpha 
levels were profiled from another 297 pigs within the resource population and found to be 
phenotypically positively correlated with viral load (r=0.25, P<0.001), viremia (r=0.15 to 
0.28, 14-28 dpi, P<0.05), IgM (r=0.20 to 0.34, 14-28 dpi, P<0.001), and IgG (r=0.11 to 
0.19, 21-28 dpi, P<0.05) antibody levels and negatively correlated with overall ADG (r=-
0.16, P<0.05). The GWAS for TNF-alpha at 21 dpi revealed a substantial proportion of 
the phenotypic variation (73.9%) could be explained by the 56,433 SNPs. Major effect 
windows were located on SSC8, SSC10, and SSC14, however, no single window 
accounted for majority of the effect [123]. The lack of association surrounding the TNF-
alpha locus on SSC7 suggests that the host genetic factors controlling this variation in 
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TNF-alpha at 21 dpi in response to PCV2 infection act through mechanisms of trans-
modulation.   
The ability to identify QTL associated with various indicator traits of PCV2 
susceptibility support the notion that host genetics plays a critical role in disease 
progression. Specifically, QTL on chromosomes 7 and 12 were identified for weekly 
viremia, antibody levels, and overall viral load following experimental PCV2 infection 
[122].  Further investigation of QTL such as these may lead to the identification of genes 
and polymorphisms responsible for reduced PCV2 susceptibility and better our 
understanding of PCV2 pathogenesis. Together this knowledge has the potential to enable 
the development of more efficient molecular solutions to better combat and prevent 
PCV2 in the future.  
 
Current PCV2 Management and Vaccines 
 PCV2 was found to be resilient to multiple common disinfectants, such as ethanol 
[124]. This resilience combined with persistent subclinical infection makes control and 
prevention of PCV2 outbreaks difficult. Even with effective disinfectants, such as bleach, 
it is impossible to completely disinfect facilities of PCV2 and prevent shedding by 
subclinically infected animals through fecal, urinary, and oronasal routes [58, 59, 124]. 
Therefore, although facility management is an important factor in preventing PCV2 
outbreaks, there is only so much that can be done to prevent this elusive pathogen. As a 
result, majority of management practices at the present time revolve around vaccination 
regimes for the entire herd for both PCV2 and secondary pathogens.  
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 There are a variety of commercial PCV2 vaccines currently on the market 
including: Ingelvac® CircoFLEX™, Porcilis® PCV, Suvaxyn PCV2® One Dose, 
Circumvent PCV™, and Circovac®.  Both Ingelvac® CircoFLEX™ (Boehringer 
Ingelheim) and Circumvent PCV™ (Intervet) are subunit vaccines utilizing killed 
baculovirus vectors injected into the host to prevent against PCV2 replication and 
shedding. The antigen of these vaccines is generated by incorporation of the ORF2 gene 
that encodes the PCV2 capsid protein into the baculovirus vector. Ingelvac® 
CircoFLEX™ is a single dose (1 mL) vaccine administered intramuscularly to piglets 3 
weeks of age or older (Boehringer Ingelheim). Circumvent PCV™ can be administered 
intramuscularly either as a single dose (2 mL) at 3 weeks of age or as a double dose 
vaccine (2 mL) as early as 3 days of age followed by a second injection (1 mL) 3 weeks 
later (Intervet). Circumvent PCV™ was tested in a randomized controlled clinical trial in 
a herd of pigs with history of PCVAD [125]. They found that vaccinated pigs had 
significantly lower mortality rates (50% reduction) and higher ADG (9.3% increase) 
during the finishing phase compared to control pigs. Vaccinated pigs were also found to 
weigh on average 8.8kg more at time of marketing [125]. Porcilis® PCV (Intervet 
International) is another subunit vaccine that contains the capsid protein of a PCV2b 
strain. This vaccine was found to prevent viremia against 4 different PCV2 genotypes 
originating from different geographic locations as well as reduce both nasal and fecal 
PCV2 shedding [126]. However, Porcilis® PCV is a double dose vaccine with the first 
injection (2 mL) administered at 3 weeks of age and the second injection (2 mL) 
administered 2-3 weeks later (Intervet), which may increase stress for the individual 
animal. Suvaxyn PCV2® One Dose is a killed-recombinant vector vaccine that contains a 
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porcine circovirus type 1-2 chimera as the antigen and is administered intramuscularly in 
a single dose (2 mL) at 3 weeks of age or older (Fort Dodge® Animal Health). 
Circovac® is a ‘whole-virus’ vaccine that contains inactivated porcine circovirus type 2 
and a mineral oil adjuvant administered in two doses 3 to 4 weeks apart to gilts and sows 
prior to breeding (Merial).   
 Various studies have been conducted to compare the effectiveness of different 
commercially available vaccines. In 2009, Takahagi et al. compared the effects of 
Ingelvac® CircoFLEX™ and Porcilis® PCV on different PCV2 genotypes in Japanese 
commercial pig farms. Mean mortality rates 8 months after implementation of 
vaccination programs decreased in farms infected with PCV2a-2 (from 20.8% to 12.1%) 
and PCV2b (from 26.5% to 13.7%), but did not significantly change in farms infected 
with PCV2a-1 (from 14.7% to 14.1%).  This indicates that vaccines can effectively 
reduce mortality rates associated with PCV2; however, the effectiveness may be 
dependent upon the PCV2 genotype in question [127].  
In 2011, a study was conducted by Lyoo et al. that compared the effectiveness of 
Suvaxyn PCV2® One Dose, Circumvent PCV™, and Ingelvac® CircoFLEX™. A total 
of 80 pigs were divided into four groups, with three groups receiving one of the vaccines 
at 3-weeks of age following the manufacturers protocol and the other acting as a control 
group. All three vaccinated groups had significantly lower PCV2 viremia compared to 
the control group at 22 weeks of age [128]. In addition, groups that received Circumvent 
PCV™ or Ingelvac® CircoFLEX™ exhibited increased ADG (0.81kg or 0.80kg, 
respectively) compared to the control group (0.74kg, P<0.05). Another study compared 
the same three vaccines, however, also assessed the effects of single and double dose for 
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the Suvaxyn PCV2® vaccine [129]. A total of 60 3.5-week old piglets were divided into 
groups and received a different vaccine or vaccine dosage. Overall, they found that 
viremia was reduced by 78.5% in pigs receiving single dose vaccines (Ingelvac® 
CircoFLEX™ and Suvaxyn PCV2® One Dose) and 97.1% in pigs that received double 
dose vaccines (Circumvent PCV™ and Suvaxyn PCV2®). They also observed a 
reduction in microscopic lymphoid lesions by 78.7% for single dose and 81.8% for 
double dose vaccines [129]. Together, these results indicate that both single and double 
dose vaccines significantly reduce PCV2 viremia and improve the growth and overall 
wellness of the animals. 
However, vaccines are not a cure all in terms of PCV2. As illustrated above, there 
are no commercially available vaccines capable of complete eradication of PCV2 viremia 
[130]. This poses a potential control problem since PCV2 can be transmitted or cause 
complications at even low levels. Specifically, one study identified a new PCV2 disease 
syndrome associated with herds vaccinated for PCV2, called Acute Pulmonary Edema 
(APE) [131]. This syndrome was first discovered in 8 farms across Kansas and Nebraska 
in piglets as young as 7-weeks of age. High levels of PCV2 DNA, but no other pathogens 
were detected in the sera and tissues of all APE affected pigs. Unlike other PCVAD, APE 
has preacute onset and results from transmission of PCV2 to young piglets prior to 
vaccination age that do not have adequate maternally derived-antibodies for protection 
[131].  
In regards to female reproductive failure, re-vaccinating gilts 3-weeks prior to 
integration into the breeding herd did not influence the proportion of mummified or still 
born fetuses in affected herds with increased rates of reproductive failure attributed to 
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PCV2 [130]. Rather, findings based on an unaffected herd from this same gilt source 
suggested that flow strategies maybe a better solution. These gilts were integrated into the 
breeding herd 9 weeks younger than gilts from the affected herds and showed no increase 
in fetal mortality or mummification, indicating that when gilts are introduced into the 
breeding herd prior to breeding may impact PCV2-associated reproductive failure [130]. 
The reason being that younger gilts have time to recover from PCV2 exposure prior to 
breeding, which protects the fetuses from vertical PCV2 transmission [130]. Although 
current vaccines are fairly effective, they are not full proof, which is why further research 
to better understand PCV2 pathogenesis is crucial for future prevention of this small, but 
mighty pathogen.  	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CHAPTER 2 
 
ANNOTATION OF QTL REGION LOCATED ON CHROMOSOME 12 
AND POLYMORPHISM DISCOVERY UNCOVERS CANDIDATE 
GENES AND NOVEL POLYMORPHISMS INFLUENCING IN VIVO 
PCV2 REPLICATION* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Parts of this chapter were submitted to PLOS Genetics (2018) 
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2.1 Introduction 
Anecdotal field data and initial experimental evidence [1, 2] described differences 
between breeds in both incidence and severity of PCVAD [3], supporting the role for host 
genetic variation in the etiology of the disease. In the first genome-wide association study 
(GWAS), host genetics was found to influence PCV2 titer and accounted for an important 
proportion of the phenotypic variation (~45%) for viral load [4]. In addition, substantial 
variation in the timing and magnitude of immune response was also observed [4, 5]. A 
subsequent study [5] extended this work by examining the influence of host genetics on 
the process of infection, based on a combination of the two previous study populations 
(n=974 F1 crossbred pigs originating from 14 genetic lines) challenged by experimental 
infection with the same PCV2b strain and genotyped with a high-density array (Porcine 
SNP60 BeadArray, 56,433 SNPs). The population structure provides substantial variation 
in linkage disequilibrium (LD) decay in order to potentially identify genomic regions that 
influence PCV2 susceptibility using a GWAS approach. In this study, we build on the 
findings of Engle et al. (2014) using both genomic and RNA sequencing, gene 
annotation, and polymorphism discovery to dissect the genomic regions associated with 
PCV2 viral load on chromosome 12 to further elucidate the role of host genetics in 
disease progression. 
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2.2 Materials and Methods 
Experimental Design: Animals, Diets, and Housing 
Experimental PCV2b challenge was conducted in nine batches that varied in size 
from 81 to 141 pigs. The genetic makeup of this resource population consisted of 974 F1 
crossbred pigs produced by 14 genetic lines generated by seven genetic programs. 
Batches 1-4 (n=386) were produced by the UNL Swine Research Unit involving Large 
White, Landrace, and Duroc commercial pigs as well as pigs from the Nebraska Index 
Line (NIL), a line selected primarily for litter size [4]. Batches 5-9 (n=588) were 
produced with genetics from PigGen Canada Consortium, which used Large White dams 
and Landrace sires [5].  
The dams of the experimental pigs had been vaccinated for PCVAD at 3 weeks of 
age with a single dose of Ingelvac CircoFLEX vaccine (Boehringer Ingelheim). The 
suppliers of the pigs also had vaccination programs for Porcine parvovirus, Erysipelothrix 
rhusiopathiae, Clostridium perfringens, Leptospirosis and Colibacillosis and tested 
negative for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Prior to 
experimental infection, the pigs tested negative for presence of PCV2 in peripheral blood 
by real time quantitative PCR (qPCR) and had a sample/positive ratio (S/P) lower than 
0.4 for IgM and 0.3 for passive IgG, the PCV2-specific antibodies [4]. Following 
infection, experimental pigs were examined daily for clinical signs of disease; weights 
and blood samples were collected at 0, 7, 14, 21 and 28 days post infection (dpi). Details 
of the experimental procedures, phenotypic and sample collection are described in Engle 
et al. (2014) and McKnite et al. (2014). 
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A validation dataset consisting of a group of 71 maternal crossbred pigs 
representing all three ALGA0110477 genotypes infected with the same PCV2b strain at 5 
weeks of age was generated using the same experimental conditions. A group of 40 pigs 
(CT and TT genotypes) vaccinated for PCV2 at 3 weeks of age were used as controls. 
The vaccinated pigs were housed in the same room with the experimentally infected pigs, 
but in different pens. 
 
PCV2b Isolate and Experimental Infection 
The PCV2b strain (UNL2014001) used for the experimental infection was 
obtained from a pig with symptoms characteristic to PMWS, the most common PCVAD 
syndrome. The strain was sequenced (accession KP016747.1) using dye terminators and 
compared to PCV2 strains available in GenBank [5]. The strain was cultured in swine 
testicular cell lines as described [4]. At an average of 36 days all the pigs were inoculated 
with the UNL2014001 PCV2b strain with a titer of 104.0 50% tissue culture infection dose 
(TCID50) intranasally and intramuscularly. 
 
Serologic Profile: Quantification of Viral DNA and PCV2-specific Antibodies 
PCV2 specific antibodies, IgM and IgG, were profiled weekly from serum using 
ELISA (Ingenasa) as described in McKnite et al. (2014). Estimates of the number of 
PCV2b copies, or viremia, was performed using viral genomic DNA isolated by QIAamp 
DNA Minikit (Qiagen) and quantified by qPCR using TaqMan Master Mix and ABI 
7900 Real Time PCR System (Thermo Scientific). The viral load for each pig during the 
entire challenge was represented as area under the curve (AUC) based on an algorithm 
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that takes into account viral levels observed at each time point following infection (0, 7, 
14, 21, and 28 dpi) fitting a smooth curve over the 28 days and summing the areas in 0.01 
time increments [6]. 
 
Host DNA Isolation, Sequencing, Polymorphism Discovery and Genotyping 
 The DNA was isolated from ear and tail tissue clips using DNeasy or Puregene 
blood and tissue kits (Qiagen). The experimental animals were genotyped using either the 
first or second generation of the Porcine SNP60 BeadArray (Illumina) that contain 
62,183 and 61,565 SNPs, respectively. Only the common SNPs present in both 
BeadArray versions (91.6%, 61,177) were mapped on Sscrofa 10.2 porcine reference 
genome assembly. The broad position of the unmapped SNPs on the original Sscrofa 
10.2, such as ALGA0110477, was predicted by linkage disequilibrium estimates (r2) with 
the mapped SNPs using “Linkage disequilibrium” option from GenSel software package 
[7].  An additional 7.2% of the previously unmapped SNPs, including ALGA0110477, 
were mapped on Sscrofa 11.1. DNA samples and SNP assays with a genotyping call rate 
below 80% were excluded from the analyses and a GenCall quality score of 0.40 was 
used as a minimum threshold for genotype quality [8], resulting in 56,433 SNPs (Sscrofa 
10.2) used in the GWAS.  
 Targeted DNA sequencing of candidate genes in the SSC12 QTL region and their 
2 – 4 kb region upstream of the transcription start sites (TSS) was performed using dye 
terminators and ABI PRISM 3100 Genetic Analyzer (Thermo Scientific) on high and low 
viremic samples. Discovery and validation of the polymorphisms detected by RNA-seq 
was based on alignment of DNA sequences using Sequencher software (Gene Codes). 
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Potential impact of the polymorphisms located in the proximal promoter on important 
regulatory motifs was evaluated using FIMO (version 4.11.3)[9] and the JASPAR 
transcription profile database (version 2016). Genotyping of polymorphisms located in 
transcribed regions and proximal promoters of candidate and surrounding genes was 
performed by multiplex assays using Sequenom MassARRAY platform and Sequenom 
iPLEX chemistry based on the manufacturer protocols (Sequenom, San Diego, CA). 
 
Genome-Wide Association Studies 
The proportion of phenotypic variance explained by host genetics for PCV2-
viremia, PCV2-specific antibodies (IgM and IgG) and average daily gain (ADGi) during 
experimental infection was estimated based on Porcine SNP60 BeadArray genotypes 
using a BayesB model [10] and GenSel software [7]. The statistical model included litter, 
pen and batch as class variables and passive IgG and age at infection as covariates. 
Bayesian regression models fit multiple SNPs in genome-wide associations, assuming 
that the marker effects result from a mixture of a point mass distribution whereby SNP 
have null effects and a distribution of non-zero effects (e.g., normal, heavy tailed). 
Bayesian analyses were based on 𝜋 equal to 0.99 that assumed a prior probability of 1% 
of the SNPs having a non-zero effect. Prior assumptions are made relative to the genetic 
and environmental variances and the proportion of markers that have a null effect on a 
specific trait of interest. These models are implemented via a Markov chain Monte Carlo 
(MCMC) sampling algorithm. The posterior means are averaged over the number of 
samples from the MCMC [11]. The Markov chain included 40,000 samples with the first 
1,000 being removed as burn-in. Markov chain was set to use every 40th sample to 
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estimate posterior distribution for the genetic variance explained by each 1 Mb window 
of the reference genome. This distribution was used to estimate the probabilities of each 
1Mb window having a variance greater than 0 or greater than the average variance 
explained by each 1Mb window as described in McKnite et al. (2014). 
Bayes Interval Mapping (BayesIM) was implemented to derive haplotype effects 
across the genome on PCVAD-related traits as described in Kachman (2015) [12]. 
Briefly, a hidden Markov model was used to generate 8 haplotype states based on SNP 
genotypes [13]. Phenotypic variation of the targeted traits was analyzed with a hierarchal 
Bayesian model. QTL were placed every 50 kb across the genome while average 
haplotype size was set to 500 kb. Genetic variances, haplotype effects, and model 
frequencies were estimated at each locus. There were 42,000 MCMC samples collected 
with the first 2,000 used for burn-in. The model included batch, litter and pen as random 
effects and IgG and age at infection as covariates. If a locus had an effect, haplotype 
effects for each cluster were modeled as independent normal random variables. 
Associations between the single marker genotypes and phenotypic variation were 
tested using a linear mixed model fitted by JMP 10.0 (SAS Inst. Inc.) that included 
marker genotype and batch as fixed effects, litter and pen as random effects while age at 
infection and IgG were used as covariates. Additive and dominance effects were 
estimated for each of the targeted DNA polymorphisms. A similar model was used to 
estimate the interaction between SNPs. 
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Novel Assembly of the Proximal End of SSC12 
Inverse PCR (iPCR), using four (AciI, AluI, HaeIII, HpaII, RsaII) and six cutter 
(EcoRI, HaeII, HincII, HindIII, KpnI, MfeI, MspA1l) restriction enzymes (New England 
Biolabs), T4 DNA ligase (New England Biolabs) and nested PCR using AmpliTaq Gold 
360 DNA polymerase (Thermo Scientific), was employed to expand the genomic DNA 
sequence surrounding the short ALGA0110477 sequence. A genomic scaffold (19 Mb) of 
the proximal end of SSC12 was constructed based on Pacific Biosciences sequencing 
reads [14]. The position of the extended ALGA0110477 sequence and all SSC12 mapped 
and unmapped SNPs were determined on the genomic scaffold using BLAT. Annotation 
of the QTL region on the SSC12 scaffold was based on RNA-seq alignments and 
BLAST, but also Ab initio approaches such as GenScan [15, 16] in combination with 
pBLAST. 
 
RNA-seq and Gene Expression Profiling 
In order to profile transcriptome changes and sequence variation related to PCV2 
infection, peripheral blood samples collected from the validation group of pigs that 
exhibited high (NTT=6) and low (NCC=5) viremic genotypes for ALGA0110477 at 0, 7, 
and 14 dpi were subjected to RNA sequencing. RNA was extracted from peripheral blood 
collected in Tempus tubes using the Tempus Spin RNA Isolation Reagent Kit (Thermo 
Scientific). RNA samples were sequenced using Ion Proton technology as described in 
the manufacturer protocol (Thermo Fisher Scientific Inc.). The adaptor-free sequencing 
reads were trimmed and filtered using Trim galore (version 0.4) [17] with low-quality 
bases in the 5’ end being removed and nucleotides with quality call less than 22 being 
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trimmed from the 3’ end. The filtered reads were initially aligned to the SSC12 scaffold 
(19 Mb) using the two-step alignment approach used for Ion Proton transcriptome data 
that includes both Tophat and local-Bowtie [18]. The reads were later also aligned to the 
new pig assembly Sscrofa 11.1. The number of reads mapped to each gene in the 
annotated QTL region was obtained using HTSeq (version 0.6.1p1)[19].  
Expression of the candidate genes across time points following PCV2 infection 
was quantified using TaqMan Master Mix and CFX384 Real Time PCR. The qPCR 
assays were designed using IDT Realtime PCR Tool software (www.idt.com) and 
sequences generated based on RNA-seq alignments. RNA was extracted from peripheral 
blood samples collected in Tempus tubes from a subset of pigs representing all genotypes 
from the validation data set that displayed extreme viral load (n=40) from 0 to 21 dpi 
using the Tempus Spin RNA Isolation Reagent Kit (Thermo Scientific). Complementary 
DNA (cDNA) was obtained using a mix of random hexamers and poly dT primers using 
First Strand cDNA Synthesis Kit (GE Healthcare Bio-Sciences). Expression of ribosomal 
protein L32 (Rpl32) gene was used for normalization. Mean normalized expression 
(MNE) values were calculated based on cycle crossing thresholds (CT) obtained for the 
technical triplicates taking qPCR efficiencies into account [20]. MNE values for SYNGR2 
p.Arg63Cys and BIRC5 g.-343delA genotypes and time points following infection were 
log10 transformed and compared by t-test. 
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2.3 Results and Discussion 
Two Genomic Loci Influence Host Genetic Effect on PCV2 Infection 
 As specified in Engle et al. (2014), this study looked at multiple key phenotypes 
including weekly viremia and PCV2-specific antibodies, overall viral load, and growth 
rate as measures of PCV2 infection. During early infection, the proportion of phenotypic 
variation explained by SNP genotypes was low, however, increased following the 
observed surge in viremia and associated immune response. For example, proportion of 
phenotypic variation accounted for by the SNP genotypes went from 19% at 7 days post 
infection (dpi) to 52% at 14 dpi for viremia and from 14% and 3% at 7 dpi to 60% and 
44% at 21 dpi for PCV2-specific IgM and IgG respectively (Table 1). However, the 
largest proportion of phenotypic variation explained by SNP genotypes was 64% for 
PCV2 viral load calculated across time points. Contrarily, the contribution of SNP 
genotypes to variation in Average Daily Gain (ADG, monitoring growth rate through 
body weight) remained low across time points throughout the challenge, 13% at 7dpi to 
7% at 21 dpi, as well as for overall ADG, 16% (Table 1). 
The initial GWAS association was performed using a BayesB model where 
individual SNPs and successive 1 Mb windows of the genome were evaluated for 
association with phenotypic variation [4]. Genome-wide average posterior distribution for 
the genetic variance was used to estimate the probability of each 1 Mb window having 
greater than the average genetic variance explained across PCV2-related traits.  The 
GWAS revealed two windows with effects greater than the average effect associated with 
both viremia and antibody phenotypes (Pr>0.90) and therefore assumed to represent 
“true” Quantitative Trait Loci (QTL) (Figure 1). One QTL was located on SSC7 near the 
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Swine Leukocyte Antigen Complex Class II (SLAII) at 28-29 Mb and the other was 
putatively located near the proximal end of SSC12, at approximately 3-4 Mb. The top 
SNPs (ALGA0039682 and ALGA0110477) associated with the largest genetic variance 
for each window both explained over 94% of the genetic variance accounted for by the 
window.  
The SNP, ALGA0110477, was associated with largest effect on PCV2 viral load, 
explaining 11.1% of the genetic variance and 7.4% of the phenotypic variance for viral 
load (Figure 2).  In the 10.2 reference assembly, this SNP was located on an unplaced 
scaffold so linkage disequilibrium estimates between ALGA0110477 and all other SNPs 
on the Porcine SNP60 BeadArray were used to determine its potential location. SNPs 
ALGA0122316, ASGA0089708, and ASGA0090188 had the highest LD estimates 
(r2<0.28) suggesting ALGA0110477 is located on the proximal end of SSC12. However, 
despite LD these SNPs or any other within the region did not show any association with 
viral load in the initial analysis. Using a different Bayesian approach, BayesIM, [12] that 
fits haplotypes across the region rather than individual SNPs, we were able to detect an 
effect of this region even when excluding ALGA0110477 from the analysis, supporting 
the initial identification of this region as a potential QTL for viral load (Figure 3).  
Since the unplaced contig containing ALGA0110477 was not annotated and the 
available sequence surrounding the SNP only extended 84 bp, inverse PCR (iPCR) was 
used to extend the proximal sequence to 1,252 bp.  The elongated sequence was then 
compared with contigs from an early version of a long read-based genome assembly of a 
pig (accession NPJO00000000) [14], which uncovered a 19 Mb scaffold that provided 
precise location of ALGA0110477 and context used for identification of candidate genes.  
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The recent release of a long read-based improved reference assembly, Sscrofa 
11.1 (GenBank accession GCA_000003025), supported more accurate ordering and 
placement of markers, including ALGA0110477 (SSC12, 3,673,576 bp), and facilitated 
finer analysis into genomic context with surrounding gene annotation. As a result, an 
enhanced profiling of the loci associated with PCV2-related phenotypes across time 
points was possible in order to distinguish the role of host genetics in innate and adaptive 
immunity.  
This analysis utilizing Sscrofa 11.1 and a BayesIM approach, identified the same 
two locations on SSC7 and SSC12 as having the largest effects on viral load (Figure 4). 
In addition, haplotype effects estimated across the proximal end of SSC12 provided 
evidence of haplotypes with divergent effects in viral load, with a peak detected at 3.7 
Mb (Figure 5). These QTL were also observed for other targeted traits (Figures 6-8). For 
viremia at 14 dpi, both QTL had similar effects, however, at 21 and 28 dpi the SSC7 QTL 
had a larger effect (Figure 6). An additional QTL on SSC8 that was not observed for 
overall viral load, had the largest effect for viremia at 14 dpi (Figure 6). For PCV2-
specific antibodies, both QTL were associated with IgM variation (Figure 7), indicative 
of active infection, starting at 14 dpi and with IgG variation (Figure 8), representing 
previous PCV2 exposure or vaccination, starting at 21 dpi. Together these results provide 
evidence of two QTL located on SSC7 and SSC12 that represent the effect of host 
variation on PCV2 infection and associated immune response.  
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Fine Mapping and Annotation of the SSC12 QTL Region  
 The 19 Mb SSC12 scaffold was used to identify genes surrounding the top marker 
ALGA0110477. Annotation of this QTL region was achieved by combining Ab initio 
gene prediction, pBLAST, and RNA-seq analysis. Thirteen potential genes with an e 
value > 7e-64 and a pBLAST score > 200 were identified. Five of these genes were found 
to be expressed in RNA-seq data of peripheral blood from pigs subjected to PCV2. These 
five genes had functions in cytokine signaling (SOCS3), inhibition of apoptosis and 
regulation of cell proliferation (BIRC5), membrane trafficking and transport (SYNGR2), 
and transmembrane ion channels (TMC6 and TMC8).   
 RNA-seq analysis of alternate ALGA0110477 homozygotes with extreme high 
and low viral loads (n=22) were used for initial polymorphism discovery and uncovered 4 
missense, 11 synonymous, and 10 UTR SNPs as well as 1 UTR indel across the five 
candidate genes. These polymorphisms were confirmed by targeted dideoxy sequencing 
of the genes. In addition, sequencing 1-2kb upstream of the Transcription Start Site (TSS) 
of BIRC5, SOCS3, and SYNGR2 identified 32 SNPs and 4 short indels. These novel 
polymorphisms and 580 SNPs on the Porcine SNP60 BeadArray were mapped to the 
scaffold using BLAT.  ALGA0110477 had the highest LD with another marker from the 
BeadArray (ASGA0086395, r2=0.55) located about 24.5kb away followed by three SNPs 
within the SYNGR2 gene (r2= 0.42-0.48) located 123.7kb away.  
A subset of samples with extreme high and low viral loads (n=307) were 
genotyped for all novel polymorphisms. These genotypes and the Porcine SNP60 
BeadArray SNPs that were mapped to the scaffold (n=632) were included in an additive 
linear mixed model analysis, which found a missense SNP (p.Arg63Cys) in SYNGR2 and 
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a 1 bp insertion (g.-343delA) located 343 bp upstream of the BIRC5 TSS have the largest 
effects on PCV2 viral load (Figure 9, F-ratio >47, P<0.0001). In addition, the phenotypic 
variance explained by each of the novel mutations was substantially larger (21-23% +/- 
6.1-6.4%) compared to ALGA0110477 (12.6 +/- 4.8%). These polymorphisms were also 
associated with large effects on all weekly viremia measures (P<0.0001) and PCV2-
specific antibodies, starting from 14 dpi for IgM and 21 dpi for IgG (P<0.0001).  The 
effects on growth during the challenge were most evident after 14 dpi as well as during 
the entire challenge period (0 – 28 dpi, P<0.0005). 
 
SYNGR2 and BIRC5 are Potential Candidate Genes Influencing PCV2 Replication 
The SYNGR2 p.Arg63Cys SNP is located in the first loop of the SYNGR2 protein 
in a region conserved across mammals [21] known to be crucial for formation of 
microvesicle membrane fraction [22]. The Arg residue is prevalent in other species (e.g., 
human, rat, cow, horse) sometimes being replaced by His (Rhesus macaque, dog), Lys 
(prairie vole, Chinese hamster) or Gln (mouse, golden hamster) while the Cys residue 
appears to be specific to swine (Figure 10). The substitution of Arg to Cys determines a 
change in charge and hydrophobicity of the loop (Figure 11). The SYNGR2 p.63Cys allele 
is favorable with the viral load of the homozygous genotype (Least Square Mean = 54.3 
units) being lower compared to the heterozygote (67.03 units, P = 0.005) and alternate 
homozygote (p.63Arg, 79.54 units, P < 0.0001). The favorable homozygous genotype 
was also associated with lower weekly viremia (P < 0.0001, Figure 12), IgM (> 14 dpi, P 
< 0.0001, Figure 13), IgG (> 21 dpi, P < 0.0001, Figure 14) and higher growth (overall 0 
– 28 ADG and > 14 dpi, P < 0.001) compared to the alternate homozygote. Expression of 
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SYNGR2 did not differ across SYNGR2 p.Arg63Cys genotypes or time points following in 
vivo PCV2 challenge.  
The 1bp deletion located 343 bp upstream of the TSS of BIRC5 (BIRC5 g.-
343delA) was found to be in high LD (r2 = 0.83) with SYNGR2 p.63Cys allele and as 
expected was associated with low viral load (P < 0.0001). The deletion was predicted to 
affect a potential motif for NR5A2, a DNA-binding zinc finger transcription factor. 
However, no significant difference in expression was observed between BIRC5 
genotypes across time points following in vivo PCV2 challenge (P > 0.17). At 14 dpi the 
homozygotes for the insertion exhibited an elevated nominal expression compared to the 
other genotypes, but the difference was not significant (P =0.061). 
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2.4 Conclusion 
In this study, host genotypes explained a substantial proportion of the phenotypic 
variation for PCV2 viremia, viral load, and immune response, with two major QTL 
identified on SSC7 and SSC12. The inability to uncover a QTL located on SSC12 in the 
previous report [4] was based on 1) a genetic structure with a very limited number of 
homozygotes for the SYNGR2 p.63Cys allele (Q = 1.2%) in the initial study compared to 
the Engle et al. (2014) dataset (Q = 18.3%), which is less favorable for detecting 
associations in additive statistical models, and 2) lower ability of ALGA0110477 to 
capture the low viremic effects of SYNGR2 p.63Cys. While in the Engle et al. (2014) 
dataset the presence of the ALGA0110477 C variant had a 65% probability of being 
located on the same haplotype with the SYNGR2 p.63Cys allele, in McKnite et al. (2014) 
this variant is found in similar proportions in haplotypes that carry different SYNGR2 
alleles (e.g. SYNGR2 p.63Cys; P = 55.9%). 
Dissection of the SSC12 QTL based on gene annotation, genomic and RNA 
sequencing uncovered a non-conservative substitution in a key domain of the SYNGR2 
gene and a single base pair insertion upstream of the BIRC5 gene associated with PCV2 
viremia and immune response. Located 41.9 kb apart, the high LD observed between 
SYNGR2 p.Arg63Cys and BIRC5 g.-343delA (r2 = 0.83) hampered the ability to 
distinguish their individual effects in the in vivo challenge dataset. In contrast, the LD 
between SYNGR2 p.Arg63Cys and other SYNGR2 SNPs was limited (r2 < 0.26), as well 
as that with BIRC5 g.-343delA and other BIRC5 polymorphisms (r2 < 0.16). Since there 
was no significant change in BIRC5 expression throughout the challenge period, we 
hypothesize that the missense SYNGR2 p.Arg63Cys mutation is the functional mutation 
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associated with PCV2 replication and not BIRC5 g.-343delA. We believe that the 
observed effect of BIRC5 g.-343delA on PCV2 viral load is due to the tight linkage of 
this polymorphism with SYNGR2 p.Arg63Cys. Additionally, we propose that the effects 
on growth and PCV2-specific antibodies are a result of the variation in viremia 
modulated by SYNGR2.  
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CHAPTER 3 
SYNAPTOGYRIN-2 INFLUENCES IN VITRO PCV2 REPLICATION IN 
PORCINE KIDNEY 15 CELL LINE* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Parts of this chapter were submitted to PLOS Genetics (2018) 
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3.1 Introduction 
 Synaptogyrin-2 (SYNGR2) is a non-neural member of the synaptogyrin family, a 
group of genes primarily expressed in the membrane of synaptic vesicles of neuronal 
cells with roles in vesicle biogenesis, exocytosis and recycling via endocytosis [1, 2]. 
There is limited information about the functional role of this member of the gene family. 
Recently, SYNGR2 was implicated as an active player in promoting viral RNA replication 
and immune evasion of thrombocytopenia syndrome virus (SFTSV), a novel tick-borne 
bunyavirus in humans [3]. SYNGR2 interacted with non-structural viral proteins to 
promote the formation of lipid–based inclusion bodies, which become virus factories 
within the cytoplasm of infected cells. SYNGR2 mRNA had been upregulated more than 
200-fold at 36 hours post infection (hpi) with SFTSV. In vitro silencing of SYNGR2 
resulted in a decrease in viral replication and a reduction in the number and size of the 
inclusion bodies, further substantiating the role of SYNGR2 in facilitating SFTSV 
infection [3].  
Following PCV2 uptake, virus-like particles (VLP) were found to be integrated 
into intracytoplasmic inclusion bodies in infected cells, in both in vivo and in vitro 
experiments [4-6]. The VLP are localized in endosomes at the initial phase of infection. 
After release from early endosomes, the viral capsid of PCV2 has been shown to induce 
acetylation of microtubular α-tubulin interacting directly with dynein, a molecular motor 
used to transport VLP cargo along microtubules to the nucleus for replication [7]. PCV2 
is a DNA virus and replication of the viral DNA takes place in the nucleus [8]. As a 
result, the involvement of SYNGR2 in endocytosis indicates its potential role in 
modulating PCV2 replication and disease progression. SYNGR2 p.Arg63Cys, the only 
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missense polymorphism identified in SYNGR2 (Chapter 2) and characterized by a 
predicted change in charge and hydrophobicity of the first loop that connects two 
essential transmembrane domains, is located in a region conserved across mammals 
(Chapter 2). In rats, the first intraluminal loop and C-terminus of SYNGR2 were found to 
be crucial for successful incorporation of the protein into vesicular membranes and 
vesicle formation [1]. Replacement of residues 67–73 in the first loop led to protein 
degradation, with residues 70–73 having the largest impact [1]. In pigs, this segment of 
four residues is analogous to amino acids 60–63.  
Considering that the location of the SYNGR2 p.Arg63Cys substitution is in a 
conserved domain involved in vesicle formation [1] and recent literature support of 
SYNGR2 affecting replication of a tick-borne human RNA virus [3], we hypothesize that 
SYNGR2 may play a role in the internalization and early release of PCV2 from 
endosomes influencing efficient trafficking of VLP to the nucleus for replication. In order 
to validate a role of SYNGR2 in facilitating PCV2 replication, we transfected Porcine 
kidney 15 cell line (PK15) with small interfering RNAs (siRNA) targeting the mRNA of 
SYNGR2 and subsequently inoculated the silenced cells with the same PCV2b isolate 
used in vivo (UNL2014001).  
The PK15 cell line has an epithelial origin and is a well-established model system 
for PCV2 innate immunity and cellular pathogenesis [9]. The purpose of transfecting the 
cells with SYNGR2-specific siRNA was to silence or suppress the expression of SYNGR2 
by utilizing a natural process known as RNA interference [10]. The siRNA are 21 to 23 
nucleotides long with sequence specificity for certain mRNA. Once integrated into the 
cell, these siRNA assemble with proteins forming an endonuclease complex and act as 
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guide RNAs targeting complementary mRNA for degradation [10]. Thus, siRNA 
modulate gene expression by degrading mRNA prior to translation, preventing generation 
of proteins. However, exogenous delivery without endogenous expression of the desired 
siRNA results in transient suppression lasting about a week in vitro [10]. By silencing 
SYNGR2, we could provide evidence of its role in PCV2 infection and impact on viral 
replication.  
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3.2 Materials and Methods 
PK15 Cell Culture, Sample Collection, and Genotyping 
 The porcine kidney cell line (PK15), was grown in DMEM high glucose media 
supplemented with 10% FBS and 1% Penicillin-Streptomycin (5,000 U/mL). Cell 
samples were collected from culture plates in PBS and centrifuged for ~1 min at 
16,000xg to pellet the cells. PBS was removed and pelleted cells were stored at -80°C. 
DNA and RNA were extracted using TRIzol reagent following the manufacturers 
protocol (Thermo Fisher). The cDNA was generated from extracted RNA using First 
strand cDNA Synthesis Kit (GE Healthcare Bio-Sciences). Dideoxy sequencing of the 
cDNA and genomic DNA was used to profile the gene sequences and genotype the 
BIRC5 and SYNGR2 variants in the PK15 cell line.  
 
In vitro PCV2 Infection of PK15 Cells and Expression Profiling 
 Cells were cultured in 12-well plates (4 cm2) with 5.0x105 cells per well and 
infected with UNL2014001 PCV2b strain (TCID50=104) when 80-100% confluent at 
MOI=0.00025. One hour following infection, cells were washed and fresh media was 
added (DMEM high glucose and 2% FBS). The cells were incubated at 37 ◦C with 5% 
CO2 for up to 5 days. Control cells were maintained the same way and mock inoculated 
with plain DMEM high glucose media. Supernatant and cells were collected at specific 
time points (0, 12, 24, 48, 72, and 96 hpi) and frozen at −80 ◦C. Viral DNA was extracted 
from supernatant using QIAamp DNA Mini kit (Qiagen). RNA, viral and host DNA was 
extracted from PK15 cells using AllPrep DNA/RNA Mini kit (Qiagen). TaqMan Master 
Mix and CFX384 Real Time PCR Detection System (BioRad) were used for 
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quantification of PCV2 and expression profiling of BIRC5 and SYNGR2 from PK15 cells. 
Expression of ribosomal protein L32 (Rpl32) gene was used for normalization of gene 
expression. MNE values of SYNGR2 and BIRC5 were log10 transformed and compared 
by t-test between control and infected cells. 
 
In vitro Silencing of SYNGR2 in PK15 Cells 
 PK15 cells were transfected 24 hours after plating in 12-well plates (4 cm2) with 
2.5x105 cells per well when ~80% confluent with two siRNA oligos targeting SYNGR2 
mRNA (siRNA-01: sense 5’-CUACAAGGCCGGAGUGGAUUU-3’, and antisense 5’-
AUCCACUCCGGCCUUGUAGUU-3’; siRNA-03: sense 5’-CCACAAGUCCGGAGAGCAGUU-
3’, and antisense, 5'-CUGCUCUCCGGACUUGUGGUU-3', Dharmacon Research) and the 
AllStars Negative Control siRNA (scramble, Qiagen) at 10nM and 20nM concentrations. 
Transfection was performed using Lipofectamine RNAiMAX transfection reagent 
(Invitrogen) following the manufacturer’s protocol. Cell samples were collected 24, 48, 
72, and 96 hours post transfection and stored at -80◦C. RNA was extracted using 
RNAeasy Mini kit (Qiagen). Real Time PCR was used to profile SYNGR2 expression. 
Following initial testing, the siRNA-01 and AllStars Negative Control siRNA both at 
20nM concentrations were used for subsequent transfections. Cells were inoculated 24 
hours after transfection following the same infection protocol described above. Statistical 
differences in viral titer between cell lines across time points were tested using a linear 
model fitted by JMP 10.0 (SAS Inst. Inc.) that included batch and cell line as fixed 
effects. Pairwise comparisons between least-squares means of the viral titers were based 
on the Tukey test. 
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3.3 Results and Discussion 
BIRC5 and SYNGR2 Gene Structure and Variants in PK15 Cells 
 Targeted cDNA and genomic DNA sequencing of the PK15 cell line for both 
genes revealed no differences in transcript structure compared to the RNAseq data for 
either SYNGR2 or BIRC5. Interestingly, only one BIRC5 isoform was observed in the 
PK15 cell line compared to four isoforms present in the RNAseq data from pig sera 
collected during the experimental challenge. The isoform includes 4 complete exons and 
was the predominate isoform observed in vivo. The PK15 cell line was also determined to 
be homozygous for the unfavorable alleles associated with increased viral load for both 
SYNGR2 p.Arg63Cys (p.63Arg) and BIRC5 g.-343delA (g.-343insA). 
 
In vitro PCV2 Infection had No Effect on Expression of BIRC5 or SYNGR2 
 Successful infection of PK15 cell culture with PCV2b inoculate was observed, 
with consistent infection profiles across three independent replications in both 
supernatant and cell samples (Figures 15 and 16).  In the supernatant we saw an increase 
in viral copies from 0 to 12 and 24 to 72 hpi, with plateaus observed from 12 to 24 hpi 
and at 96 hpi (Figure 16). In the cell samples we observed a decrease in viral copies per 
well between 0 and 12 hpi, which is expected because at 0 hours the cells are saturated 
with PCV2 virions, however, only a portion of the virions will successfully enter the cell 
and able to be observed at 12 hpi (Figure 15). The rest of the virions will be released and 
present in the supernatant. From 12 hours onward we see a consistent increase in PCV2 
copies, indicating successful PCV2 replication and proliferation, with PCV2 titer peaking 
at 72 hpi and decreasing slightly at 96 hpi likely due to cell loss (Figure 15).  
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 Expression profiling of BIRC5 and SYNGR2 across time points post infection 
showed no significant difference in expression for either gene between infected and 
control cells, corroborating in vivo findings. Although expression of SYNGR2 increased 
and BIRC5 decreased over the 4-day period following infection, these changes were 
observed in both infected and control cells (Figures 17 and 18). The lack of evidence to 
suggest that PCV2 infection triggers changes in gene expression strengthened our 
hypothesis that SYNGR2 p.Arg63Cys is the functional source responsible for variation in 
PCV2 replication.  
 
Viral titer was Decreased in SYNGR2-Silenced Cells Infected with PCV2 
 We evaluated two siRNA (siRNA-01 and siRNA-03) at two different 
concentrations (10 nM and 20 nM) and found that siRNA-01 was the most efficient to 
knockdown mRNA level of SYNGR2 compared to the cells subjected to a scramble 
siRNA control, with an average reduction of 82.2% in SYNGR2 mRNA level observed 
starting 24 hours after transfection (≈0 hpi, Figure 19). PK15 cells with the expression of 
SYNGR2 silenced were then infected with PCV2 24 hours after transfection. A reduction 
in viral titer was observed in the SYNGR2 silenced cells subjected to PCV2 starting at 48 
hpi when compared to scramble siRNA and non-transfected control cells, indicating a 
role of SYNGR2 in viral replication (P <0.05, Figure 20). The viral titer across time points 
was not statistically different between the scramble siRNA and non-transfected control 
cells (P > 0.54, Figure 20). 
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3.4 Conclusion 
In our study, we observed similar results to those reported by Sun et al. (2016), in 
that silencing of SYNGR2 expression in PK15 cells was associated with a significant 
reduction in PCV2 titer, indicating a role of SYNGR2 in promoting viral replication. 
Although, we did not observe an increase in SYNGR2 mRNA levels following in vitro 
(like in Sun et al. study) or in vivo infection with PCV2, this may simply reflect important 
distinctions between SFTSV and PCV2. For instance, SFTSV is an RNA virus with the 
capacity to replicate within intracytoplasmic inclusion bodies, or viral factories. As Sun 
et al. (2016) illustrated, SYNGR2 is a component of these vesicles and necessary for their 
formation. As SFTSV replicates, more viral factories will be required for viral 
proliferation, resulting in increased levels of SYNGR2. PCV2, on the other hand, is a 
DNA virus and can only replicate in the nucleus of host cells. Therefore, the potential 
role of SYNGR2 in PCV2 infection likely takes place prior to viral replication and may 
not require such an increase in SYNGR2 expression, but rather specific SYNGR2-PCV2 
interactions. Since the position of this substitution is clearly located in a loop domain and 
not part of a transmembrane region as indicated by Janz and Sudhof (1998) and predicted 
by PSIPRED [11], an interaction between SYNGR2 and a ligand is favored compared to 
the potential impact of SYNGR2 p.Arg63Cys on overall protein folding or loop 
conformation (Figures 21 and 22). Therefore, as long as there is an adequate level of 
SYNGR2 protein, efficient PCV2 infection is possible.  
While further research is required to define the mechanism in which SYNGR2 and 
its alleles alter PCV2 multiplication, we propose the following theories based on current 
findings and the nature of PCV2 infection. We hypothesize that the interaction between a 
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ligand and the protein encoded by the SYNGR2 p.63Cys allele may 1) reduce the ability 
of the virus to enter the cell through the endocytic pathway or be internalized into 
endosomes following cellular entry, 2) alter capsid release from early endosomes, thus 
preventing migration of the virus to the nucleus for DNA replication or 3) decrease the 
efficiency of virus uncoating, an essential step required for successful replication. 
Additional studies utilizing gene editing technology will also be necessary to provide 
direct experimental evidence of the impact of allelic substitution at the SYNGR2 
p.Arg63Cys locus on PCV2 replication, however, based on our data we believe the 
SYNGR2 p.Cys63 variant decreases the ability of  PCV2 to replicate following infection. 
The significant decrease in viral titer observed following an 80% reduction in SYNGR2 
expression in vitro, despite presence of the unfavorable BIRC5 variant, provides strong 
evidence of the involvement of SYNGR2 in PCV2 infection. Together with the lack of 
expression differences for BIRC5 in vivo and in vitro in response to PCV2 infection, 
strongly suggests the only missense mutation, SYNGR2 p.Arg63Cys, to be a plausible 
quantitative trait nucleotide (QTN) for PCV2 susceptibility. These findings not only 
contribute to a better understanding of the critical players involved in pathogenesis of 
PCV2 infected cells, but also the role of host genetics in viral disease susceptibility. 
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TABLES 
 
Table 1. Proportion of phenotypic variance explained by SNPs from Porcine SNP60 
BeadArray using Bayes B of PCV2-related traits days post infection (dpi) with 
PCV2. 
	  
Trait/dpi 7 14 21 28 0-28 
Viremia 0.19 0.52 0.45 0.39 0.64 
IgM 0.14 0.60 0.44 0.52  
IgG 0.03 0.08 0.44 0.38  
      
Trait/dpi 0-7 7-14 14-21 21-28 0-28 
ADG 0.13 0.11 0.07 0.07 0.16 
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FIGURES 
 
Figure 1. Probability of a 1 Mb window to have an effect above the average effect of 
the genome-wide 1 Mb windows estimated using BayesB on overall Average Daily 
Gain (ADG) and PCV2 viral load (AUC). The genetic variance for PCV2 viral load 
explained by the top two 1 Mb windows that included ALGA0039682 (SSC7) and 
ALGA0110477 (SSC12) have effects above the 1 Mb window average effect (P > 0.90). 
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Figure 2. Genome-wide association between 56,433 SNPs and PCV2b viral load 
using BayesB. Each dot represents the proportion of genetic variance explained by an 
individual SNP. The x-axis represents the position of each SNP in the swine genome 
using Sscrofa 10.2 assembly. The y-axis represents the contribution of each SNP to the 
genetic variance. Alternate colors represent autosomes, from SSCs 1 to 18, chromosome 
X and Y followed by a set of SNPs without a genomic location. ALGA0110477 is located 
in the last group of SNPs with the genomic location unassigned, but characterized by a 
model frequency of 0.96. 
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Figure 3. Genome-wide association between 54,946 SNPs and PCV2b viral load 
using BayesIM. Marker ALGA0110477 and all other unmapped SNPs were excluded 
from the analysis. Each dot represents the model frequency associated with each 50kb 
QTL. The X-axis represents the position of the QTL across the swine genome using 
Sscrofa 10.2 assembly. The Y-axis represents the model frequency of the association 
between a QTL and PCV2 viral load. Alternate colors represent autosomes, from SSC1 to 
18. 
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Figure 4. Genome-wide association between 51,592 SNPs and PCV2b viral load 
using BayesIM. Each dot represents the model frequency associated with each 50kb 
QTL. The X-axis represents the position of the QTL across the swine genome using 
Sscrofa 11.1 assembly. The Y-axis represents the model frequency of the association 
between a QTL and PCV2 viral load. Alternate colors represent autosomes, from SSC1 to 
18. 
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Figure 5. Haplotype effects for PCV2 viral load across the proximal end of SSC12 
estimated using BayesIM model. 
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Figure 6. Genome-wide association between 51,592 SNPs and PCV2b viremia using 
BayesIM. Each dot represents the model frequency associated with each 50kb QTL. The 
X-axis represents the position of the QTL across the swine genome using Sscrofa 11.1 
assembly. The Y-axis represents the model frequency of the association between a QTL 
and PCV2 viremia. Alternate colors represent autosomes, from SSC1 to 18. 
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Figure 7. Genome-wide association between 51,592 SNPs and PCV2-specific IgM 
using BayesIM. Each dot represents the model frequency associated with each 50kb 
QTL. The X-axis represents the position of the QTL across the swine genome using 
Sscrofa 11.1 assembly. The Y-axis represents the model frequency of the association 
between a QTL and IgM following PCV2 infection. Alternate colors represent 
autosomes, from SSC1 to 18. 
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Figure 8. Genome-wide association between 51,592 SNPs and PCV2-specific IgG 
using BayesIM. Each dot represents the model frequency associated with each 50kb 
QTL. The X-axis represents the position of the QTL across the swine genome using 
Sscrofa 11.1 assembly. The Y-axis represents the model frequency of the association 
between a QTL and IgG following PCV2 infection. Alternate colors represent autosomes, 
from SSC1 to 18. 
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Figure 9. Association results between the genotypes of the DNA polymorphisms 
mapped to the 19 Mb scaffold of the proximal end of SSC12 and PCV2 viral load 
using a linear mixed additive model. The line represents a smoother with a default λ of 
0.05. SYNGR2 p.Arg63Cys and BIRC5 g.-343delA were associated with the largest 
effects on PCV2 viral load (F-ratio > 47, P < 0.0001). 
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Figure 10. Sequence alignment of the first loop of SYNGR2 across mammalian 
species. The red block indicates a conserved region demonstrated to be important in 
successful incorporation of the protein into vesicular membranes and vesicle formation. 
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Figure 11. Hydrophobicity profile of the SYNGR2 Arg63Cys polypeptides based on 
the Kyte and Doolittle scale (the window consisted of 9 amino acid residues). An 
increase in the hydrophobicity score was observed in the predicted SYNGR2 p.63Cys 
polypeptide. 
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Figure 12. Least square means (LSM) and standard errors of the SYNGR2 
p.Arg63Cys genotypes (63Cys/63Cys - green, 63Arg/63Cys - red, 63Arg/63Arg - blue) 
across weekly viremia measures following PCV2 challenge (n=307).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Significant difference between alternate homozygotes (P <0.0001) 
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Figure 13. Least square means (LSM) and standard errors of the SYNGR2 
p.Arg63Cys genotypes (63Cys/63Cys -green, 63Arg/63Cys-red, 63Arg/63Arg-blue) 
across weekly IgM PCV2-specific antibody following PCV2 challenge (n=307).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
*Significant difference between alternate homozygotes (P <0.0001) 
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Figure 14. Least square means (LSM) and standard errors of the SYNGR2 
p.Arg63Cys genotypes (63Cys/63Cys -green, 63Arg/63Cys-red, 63Arg/63Arg-blue) 
across weekly IgG PCV2-specific antibody following PCV2 challenge (n=307). 
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Figure 15. PCV2 copy number from PK15 cells following inoculation with the 
UNL2014001 PCV2b strain. Number of viral copies is expressed as the mean log10 
copies/well for 3 independent replicates with errors bars representing standard error of 
the mean.  
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Figure 16. PCV2 copy number from supernatant samples following inoculation with 
the UNL2014001 PCV2b strain. Number of viral copies is expressed as the mean log10 
copies/uL per 200 uL supernatant sample for 3 independent replicates with errors bars 
representing standard error of the mean. 
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Figure 17. Expression of SYNGR2 in PK15 infected and control cells following 
inoculation with UNL2014001 PCV2b strain. Expression represented as the mean 
log10 MNE across 3 independent replicates with error bars representing standard error of 
the mean.  
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Figure 18. Expression of BIRC5 in PK15 infected and control cells following 
inoculation with UNL2014001 PCV2b strain. Expression represented as the mean 
log10 MNE across 3 independent replicates with error bars representing standard error of 
the mean. 
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Figure 19. Expression of SYNGR2 in PK15 cells transfected with SYNGR2 specific 
siRNA-01, scramble siRNA, and non-transfected controls following inoculation with 
UNL2014001 PCV2b strain. Expression represented as mean log10 MNE relative to 
controls across 3 independent replicates with error bars representing standard error of the 
mean.  	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Figure 20.  PCV2 copy number from PK15 cells transfected with SYNGR2 specific 
siRNA-01, Scramble siRNA, and non-transfected controls following inoculation with 
UNL2014001 PCV2b strain. Number of viral copies from PK15 cells is expressed as 
mean log10 copies/well across 3 independent replicates with error bars representing 
standard error of the mean.  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*Significant difference between siRNA_01 and Scramble or Control (P <0.05) 	  
* * * 
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Figure 21. Secondary structure of SYNGR2 p.63Cys allele predicted by PSIPRED  
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Figure 22. Secondary structure of SYNGR2 p.63Arg allele predicted by PSIPRED  
	  
 
